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ABBREVIATIONS 
 
 
Ab                 antibody 
ACPA           anti-citrullinated protein antibodies 
Arg               arginine 
bp                 base-pair 
CitH3           citrullinated histone 3 
Cl-am           chlore-amidine 
CNS             central nervous system 
cPAD           chick peptidyl arginin deiminase 
Cys               cysteine 
DMSO         dimethyl sulfoxide 
E11               embryo at day 11 of development 
E15               embryo at day 15 of development 
EtBr              ethidium bromide 
FBS              fetal bovine serum 
GFAP           glial fibrillary acidic protein 
H1                histone 1 
H2A             histone 2A 
H2B             histone 2B 
H3               histone 3 
H4               histone 4 
HDAC        histone deacetylases 
HLA           human leukocyte antigen 
hPAD          human peptidyl arginine deiminase 
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HS               horse serum 
Lys              lysine 
MBP           myelin basic protein 
MS             multiple sclerosis 
NAWM      normal appearing white matter 
P12             passage 12 
P30             passage 30 
PAD           peptidyl (or protein) arginin deiminase 
PBS            Phosphate Buffered Saline 
PFA            paraformaldehyde 
PI                isoelectric point 
PVDF          polyvinylidene fluoride 
RA              rheumatoid arthritis 
SAHA         suberoylanilide hydroxamic acid 
SDS            Sodium Dodecyl Sulphate 
TAE           Tris-Acetate EDTA 
TBST         Tris Buffered Saline Tween 
Thaps         thapsigargin 
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"Study on the role of protein deiminases in the nervous system" 
 
 
Citrullination (deimination) is the conversion of protein-bound arginine to citrulline. Citrullination 
is catalyzed by a family of calcium-dependent enzymes, the peptidylarginine deiminases (PADs). In 
mammals there are five PADs (PAD1, PAD2, PAD3, PAD4 and PAD6), whereas only 3 are found 
in chicken (PAD1-3). PAD isoenzymes are widely distributed in mammalian tissues and several 
studies suggest that citrullination occurs in extreme conditions such as during apoptosis, and during 
differentiation, when there is an increase in intracellular calcium concentration. Citrullination of 
different PAD target proteins has been associated with certain diseases, such as Alzheimer's disease, 
multiple sclerosis, rheumatoid arthritis and psoriasis.  In humans, citrullination might be an early 
marker in neurodegenerative diseases. 
The role of PADs and citrullination in some human diseases is poorly understood and the 
physiological roles of PADs have yet to be fully investigated. At present citrullination is believed to 
play a role in myelin sheath formation and during keratinocytes terminal differentiation. Recent 
studies in mouse have suggested that PAD4 regulates histone methylation at the p21/WAF1/CIP1 
promoters in a p53-dependent manner. 
The group of PF at UCL Institute of Child Health in London has identified PAD3 among calcium-
dependent molecules differentially regulated in response to spinal cord injury at stages of 
development permissive (E11) and non-permissive (E15) for regeneration in chick embryos. 
Consistent with the up-regulation of PAD3 in spinal cords injured at E15, more extensive 
citrullination was observed after injury at this stage. This paralleled high apoptosis and significant 
tissues loss in injured E15 spinal cords. Following treatment at the time of injury with a PAD 
inhibitor, Cl-amidine, the secondary injury response in E15 spinal cord was greatly reduced. 
 
The aim of my project was first to see if it was possible to model the injury response in neural cells 
in vitro to eventually establish a model for studying PAD, citrullination and injury response in 
human neural cells and secondly I tried to better characterize expression pattern and possible role(s) 
of PAD, focusing mainly on PAD3, in neural cell death and survival initially using neural 
progenitor cells derived from E7 (embryonic day 7) chick midbrain (cMB cells), which were shown 
to express PAD3 both at the protein and mRNA level and subsequently in a human neural tumor 
cell line, the neuroblastoma cell line LAN5.  
To this purposes we first studied the effects of PAD inhibition, using Cl-amidine, and PAD 
activation, using thapsigargine to raise intracellular calcium, on expression and cellular localization 
of PAD and on citrullination of a PAD target, histone 3 (H3) in cMB cells. In some experiments 
chick midbrain cells from E7 embryos were treated also with the p53 inhibitor, pifithrin, to assess 
whether p53 is required for PAD activity. 
Thapsigargin treatment induced significant cell death, but this was reduced by pretreating the cells 
with Cl-amidine. Reduction of cell death upon PAD inhibition parallels the in vivo finding in the 
injured chick spinal cord. 
Significantly, PAD3 mainly localized to the nucleus in cMB cells at passage 12 following 
thapsigargine treatment, whereas it remained largely cytoplasmatic in controls and cells pre-treated 
with Cl-amidine. Citrullinated H3 (CitH3) was not restricted to the nucleus in thapsigargine-treated 
cells while it is definitely nuclear in control and Cl-amidine treated cells. These results suggest that 
the PAD-associated apoptotic effect is likely due to PAD activity in the nucleus and that increased 
citrullination of H3 results in its export from the nucleus. As cMB cells were found to become 
senescent and die around passage 30 (P30), we investigated whether expression of PAD3 and CitH3 
changed with time in culture. At P30 PAD3 was largely nuclear both in control and treated cells 
(thapsigargine/Cl-amidine), and CitH3 distribution resembled that observed at P12 following 
thapsigargine-treatment. No changes in PAD3 localization were observed upon thapsigargine/Cl-
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amidine-treatments at P30, unlike at P12 where PAD3 localized in the nucleus only in 
thapsigargine-treated cells. Western blotting showed no differences in the amount of CitH3 among 
the different treatments. These results suggest an increased nuclear activity of PAD3 and increased 
turnover of CitH3 with aging that may be associated with cellular senescence and death. 
As certain tumor cell lines were reported to express PADs, we assessed expression of PAD3 and 
PAD4, another PAD that can localize to the nucleus, and the response to thapsigargine and Cl-
amidine treatment in LAN5 cells. PAD3 and PAD4 appeared to be mainly perinuclear, and their 
expression and localization was not affected by any drug combination (assessed by 
immunocytochemistry). Western blotting and immunocytochemistry showed that also CitH3 
amount and localization were not affected in treated cells. These results parallel to what observed in 
P30 chick cells. 
In addition to an effect on cell death, PAD activity was found to play a role in cell adhesion. When 
plated in the presence of Cl-amidine, most cMB cells did not attach to the dish, but were able to do 
so upon removal of Cl-amidine. Therefore their adhesion ability rather than survival appear to be 
affected. When cells were grown in neural differentiation medium (serum-free) to study a possible 
role of PAD in differentiation, such recovery was not observed.  However, Given that PAD3 
expression was observed both in cell positive and negative for the neuronal marker,  
ß3-tubulin, and that in the presence of serum Cl-amidine did not affect expression of ß3-tubulin, as 
indicated by immunocytochemistry and Western blotting, a role for PAD in neuronal differentiation 
does not seem to be likely.  
The expression  pattern of PAD3 during chick embryonic development was assessed by mRNA 
analysis and RT-PCR in tissues dissected from embryos in various stage of development. 
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INTRODUCTION 
 
Epigenetics refers to the several mechanisms modulating changes in gene expression independently 
of modifications of the primary DNA sequence . Epigenetics regulation of gene expression has been 
shown to have a critical role in the development of  organs and tissues. Several factors contribute to 
epigenetic regulation of gene expression, such as microRNA, DNA methylation and post-
translational modifications of nucleosomal histones (Gyorgy et al., 2006). 
Posttranslational modifications of proteins are biological processes that give critical structures and 
functions to protein after synthesis and they are crucial because may alter physiological and 
chemical properties, folding, distribution, stability, activity and consequently the function of the 
target proteins, some of which being involved into diseases. Methylation, acetylation, 
phosphorylation, ubiquitination and citrullination are examples of posttranslational modifications 
having a significant role in epigenetics mechanisms control including the modifications of 
nucleosomal histones. 
Nucleosomes are the basic unit of chromatin; they are formed by 150pb DNA wrapped around 
octamers  histones, of which four major have been identified: H2A, H2B, H3 and H4.  
H1 is an  additional histone protein,  distributed in the liker regions between two confinant 
octamers. 
Structural studies of nucleosomes have revealed that histones are arranged as globular core whit the 
N-terminal tails projecting outward and for this reason the amino acids on the tails are the most 
easily accessible targets to enzymatic activities. 
The major post-translational modifications occurring on nucleosomes are: 
ACETYLATION : it is the transfer of acetyl groups to the lysine residues in the tail of     
nucleosomal histones. It is a reaction catalysed by  family of enzymes called histone 
acetyltransferases (HAT) and functionally correlated with transcriptionally competent chromatin. 
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DEACETYLATION: it is the removal of acetyl groups, catalysed by a family of histone 
deacetylases (HDAC) and is functionally correlated with transcriptionally inactive chromatin. 
METHYLATION: It is a process of adding one, two or three methyl groups to lysine and        
arginine on histone tails. Depending on the specific lysine and arginine, methylation may result in 
gene activation, such as the methylation on Lys 4 residue on histone H3 and on Arg 3 on histone H4 
and Arg 17 oh histone H3, or may results in gene repression, such as methylation on Lys 9 and  27 
on H3 and on Arg 8 on H3 and Arg3 on H4. 
 DEMETHYLATION: lysine and arginine methylation are reversible and can  be removed by 
specific deiminases, such as human peptidylarginine deiminase 4 (PAD4) which convert arginine 
into citrulline. (Gyorgy et al., 2006). 
 
             Fig.1: histone modifications regulate chromatin structure and functions. From: “Research Summary 
“Epigenetic Histone Modifications in Cell differentiation and Cancer” Wang Y. Web site 
http://bmb.psu.edu/directory/yuw12” 
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PAD GENE FAMILY AND CITRULLINATION  
 
Citrullination is the conversion of arginine to citrulline, a reaction of protein-deimination, catalysed 
by a family of calcium binding enzymes, the peptidylarginine deiminases. Recently, vertebrate 
PADIs were categorized into five isoenzymes (PAD1-6), based on their amino acid sequences, 
substrate, specificity and tissue 
location. Meanwhile, with the 
development of genomic project and 
advanced genomic prediction 
approach, it was found that only the potential PAD, similar to PAD2 exist in fish ( Danio rerio, 
Takifugu rubriepes and Tetraodon nigrouris) and amphibians (Xenopus leavis). Otherwise, there 
are three isotypes ( cPad1-3) predicted in birds (Gallus gallus). In mammals, the chromosomal 
 
Fig.2 Phylogenetic relationship of a part of PAD enzymes from representative species. From: ”Transcriptional regulation of peptidylarginine 
deiminase expression in human keratinocyte, S.Ying et al”,2008.  (A) PAD1 genes published  or predicted from genomic researches. Following the 
species evolution only one isotype of PAD exists in fishes (zebrafisch, Danio rerio) and amphibians (African clawed frog, Xenopus leavis,), three 
types in birds (chicken, Gallus gallus), and five types in mammals (mouse, Mus musculus; human, Homo sapiens). (B) Phylogenetic tree of the 
PADI gene. The unrooted phylogenetic tree was constructed from available PADI genes by ClustalW 1.83 on DDBJ website. Distancese were 
calculated according to Kimura method as default on the website (http://clustalw.ddbj.nig.acjp/top.j.html). The tree view was generated by 
TreeView (win32) 1.66 and the bar rapresents one substitution per 10 positions. GeneBank accession numbers of the cDNA sequences used in 
alignments are as follows; zpadi2: NM-200112: fpadi2: NM_001086900, cpadi1-3: XM_425729, XM_425730 and NM_205043, respectively; 
mPadi1-6: NM_011059, NM_008812, NM_011060, NM_011061 and NM_153106, respectively; hPADI1-6: NM_013358, NM_007365, 
NM_016233, NM_012387 and NM_207421, respectively. The records of these sequences are predicted using automated genomic tools by NCBI 
annotation. 
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localization of all five types of PAD genes has been determinated in mouse (Mus musculus), rat 
(Rattus norveicus), and human (Homo sapiens). As shown in Fig.2A it seems that the number of 
PAD isotypes increases by the biological evolution. Furthermore, the phylogenetic tree of the PADI 
genes constructed using ClustalW from available cDNA sequences data on NCBI, shows that the 
PAD2 gene is likely to diverge first from the common ancestor, the other PADI gene being derived 
by duplication during phylogenetic development (Fig2B). This presumption is also consistent with 
phylogenetic analysis of PAD amino acid sequences. Moreover, PADI2 is expressed in the broadest 
tissues distribution and this suggests that PAD2 retains an ancestral function and it is also 
speculated that the other PADI genes have evolved to be expressed in specific tissues and to target 
specific substrates. 
In humans PADI-1,-3,-4, and 6 are located at a single cluster 
which spans on about 334,7 kb region on chromosome 1p36.1. 
PADI-2 is the odd  one-out: the largest gene in the family, it is 
located farther away from the other genes and transcribed in the 
opposite direction. This peculiar genomic organisation is 
conserved among species and the localisation, direction of the 
genes, the intragenic sequence lengths, exon-intron boundaries 
and the coding sequences are similar between mouse and man. 
Each of the PADI genes has the same exon/intron structure and 
the genomic structure of the       PAD gene cluster is conserved as 
well in all mammals. (Ying S. et al.; 2008) 
 
 
 
 
Fig3:genomic localization of PADI1-6:  
The five PADI genes clusters are located on 
Chromosome 1p36.1 The organization and  
orientation   are indicated by the arrows. From: 
”Transcriptional regulation of peptidylarginine 
deiminase expression in human keratinocyte, 
S.Ying et al”, 2008 
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PADI isoenzymes are widely distributed in mammalian tissues: 
 PAD1 is predominantly expressed in the epidermis and the  uterus 
 PAD3 in the hair follicles and CNS 
 PAD4 in neutrophils, eosinophils and oligodendrocytes.  
 PAD6 has been detected in eggs, ovaries and early embryos 
 PAD2 is ubiquitous, expressed in skeletal muscles, spleen, brain, secretory glands etc.  
The proposed catalytic mechanism for these enzymes is showed below: 
During the reaction the arginine is linked by the Cys residue of the PAD establishing a tetrahedral 
adduct with release of ammonia; the adduct is then cleaved by the nucleophilic attack of a water 
molecule that regenerates the Cys residue and forms the  
keto-group. 
 
 
 
 
 
 
 
 
 
In this way both ammonia group and the strong basic charge ( pI = 10,76) of arginine are lost and 
the resulting citrulline is a neutral amino acid that can influence and modify the charge distribution, 
ionic and hydrogen bond and  give to protein a “more opened “ conformation which could have a 
critical biological function and which is easier attached by proteases. 
Fig4: catalytic mode of peptidylarginine deiminase (PAD). From: ”Transcriptional regulation of peptidylarginine 
deiminase expression in human keratinocyte, Ying et al”, 2008 (A) The chemical reaction of PAD that catalyses the 
conversion of protein-bound arginine residues to citrulline redisues (protein deimination) in the presence of calcium ion. 
(B) A model of deimination effect. PAD action results modification which alter the charge of residues from positive to 
neutral, probably resulting in the unfolding of target proteins. It could induce dissociation of protein A/B complex, or the 
opposite, enable the association of protein C/D complex. 
  
 15 
Several experiments reported in literature suggest that citrullination occurs only in extreme 
conditions, such as during apoptosis, and during differentiation, when the calcium concentration get 
higher than in physiological conditions within PADs are inactive.  
Citrullination is also involved in pathological conditions such as rheumatoid arthritis and multiple 
sclerosis. 
 
PHYSIOLOGICAL ROLES OF CITRULLINATION 
 
Nuclear substrates 
Nakashima et. al (2002) discovered that PAD4 is the isoenzyme associated with apoptosis; in 
granulocytes, during programmed cell death the intranuclear calcium concentrations are high 
enough to active PAD4 to its maximal activity that results in non-specific deimination histones that 
dramatically reduce their positive charges affecting nucleosomal stability. Citrullination of histones 
causes the nucleosomes to open up (weak connection among DNA and less basic proteins) and 
expose DNA to nucleases. 
More recent studies (Li P. et al. 2010) show histone Arg methylation and Lys acetylation as 
modifications which cooperatively regulate the expression of p53-target genes in 293T cells. PAD4 
citrullinates histone arginine and momomethyl-arginine residues thereby regulating histone Arg 
methylation; PAD4 serves as a p53 corepressor to regulate histone Arg methylation at the p53-
target genes p21/WAF1/CIP1 promoter. Histone deacetylase (HDAC2) and PAD4 interact with p53 
through distinct domains an simultaneously associate with the p21 promoter to repress gene 
expression. 
After DNA damage, PAD4 and HDAC2 dissociate from p53 target gene promoters with a 
concomitant increase in histone Lys acetylation and Arg methylation at these promoters. p53 is 
known to recruit corepressors, such as HDAC1 and HDAC2, to regulate gene expression. Because 
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of PAD4 has not distinguishable motif for DNA binding and the inhibition of PAD4 increased p21 
expression, it is assumed thatPAD4 might be targeted to specific gene promoters by transcription 
factors, such as p53 to modify histones. 
The increase in p53-target gene expression after both Cl-amidine and SAHA (HDAC2 inhibitor) 
treatments suggest that a combination of these two inhibitors may more effectively inhibit cancer 
cell growth. ( P Li et al., 2010). 
 
Cytoskeletal proteins 
In the epidermis keratinocytes coexist in several states of differentiation to maintain the 
homeostasis of the tissue so as to assure its vital barrier function protecting the body against 
physical, chemical and biological insults. 
In the epidermis, PAD1 has been 
immunodetected throughout the tissue, PAD2 
in the superbasal living keratinocytes, and 
PAD3 in the granular keratinocytes and in 
the deeper corneocytes; PAD4 and PAD6 are 
not expressed. 
Cytokeratin is an intermediate filament 
produced by keratinocytes and determines 
the consistency of skin, hair and nails. 
During terminal differentiation keratinocytes travel from the basal layers of 
the epithelium to the upper areas before undergoing cell death. During this 
process the intracellular environment is exposed to increasing calcium concentrations that gradually 
activate PAD1, 2 and 3 (Vossenaar et al, 2003). Three molecules are known to be deiminated in the 
epidermis: filaggrin and keratins K1 and K10. Citrullination enables these proteins to bind to each 
 
Fig5 : immunoistochemical  
location of PAD1-3 in human 
epidermis. Bar=20μM. As shown, 
PAD1 was detected in the entire 
epidermis with an increasing 
intensity gradient from the basal 
to the granular layer. PAD2 was 
mainly detected in both   the 
spinous and granular layers with 
a more intense staining of the 
latter, whereas PAD3 expression 
was shown to be restricted to the 
granular layer and lower stratum 
corneum. 
From: ”Transcriptional 
regulation of peptidylarginine 
deiminase expression in human 
keratinocyte, S.Ying et al”, 2008 
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other by reducing their isoelectric point. Native cytokeratin and loricrin have very low affinity for 
each other, since both proteins are strongly basic; citrullinated keratin indeed, binds well to loricrin 
and to desmoplakin (desmosomal protein that helps the keratin matrix to extend transcellulary). 
Keratin citrullination has also been implicated in the pathomechanisms of psoriasis. 
Vimentin is an intermediate filament expressed by various cells. The head domain of vimentin 
contains many β-turns  that could easily be deiminated. Both phosphorylation and deimination 
reduces the isoelectric point of the head domain of vimentin; as result, the protein loses its ability to 
polymerise. During apoptosis when the intracellular calcium concentration is very high, activation 
of PAD enzymes results in the complete loss of vimentin intermediate filament network through the 
high rate of head domain deimination. This mechanism could play a role in the morphological 
changes associated with apoptosis (Asaga et al. 1998) 
Another cytoskeletal protein is glial fibrillary acid protein (GFAP), which is specific to astrocytes 
the major intermediate filament in these cells. GFAP exists in various isoforms, and some of them 
are citrullinated and present in the brain of adult rats. The physiological role of GFAP deimination 
is still unknown, however, during kainate acid or hypoxia induced neurodegeneration, both the total 
amount of GFAP and its level of citrullination increased in the astrocytes.  
PAD2 protein is found in vivo in astrocytes, microglial cells and in vitro in oligodendrocytes; 
normally PAD2 seems to become activated during neurodegeneration (under hypoxic conditions, 
the amount of PAD2 mRNA is increased). 
GFAP deimination is characteristic for certain diseases, such as Alzheimer’s in humans and 
experimental autoimmune encephalomyelitis in mice (EAE). This raises the possibility that 
citrullination could be an early marker in neurodegenerative diseases. (Citrullination: A 
posttranslational modification in health and disease,  Gyorgy et al. 2006). 
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Myelin basic protein 
A key element in myelin sheat formation is the lipid-protein interaction based on ionic interactions 
between negatively charged ( phosphatidyl-serine and sialic acid containing gangliosides) and the 
basic proteins (MBP, lipophilin). Any alteration of the isoelectric point of these proteins can cause 
dramatic changes in the interaction with lipids ( Boggs et al. 1999). 
MBP is synthesised in various isoforms that later undergo several posttranslational modifications, 
such as deimination, deimination, sulphoxyde-formations, methylation and phosphorilation 
(Pritzker et al., 2000). Citrullination of MBP reduces the interactions with the negatively charged 
phosphatidylserines due to the loss of basic residues. The ratio of deiminated MBP/ total MBP is 
crucial in the physiological function of CNS; native MBP contains several arginines (not 
deiminated) and forms very tight and compact myelin sheaths. These can reorganise only slowly. 
Citrullinated MBP is not able to form such compact sheaths (Beniac et al, 2000), on the hand, the 
lipid complex formation is more rapid. The MBP Cit/ total MBP ratio changes amazingly in 
postnatal life: under 2 years of age nearly all MBP is deiminated. Above 4 years, the ratio is only 
18% and this ratio remains constant in adults. Changes of MBP-Cit/ total MBP correlate with the 
high plasticity of the brain of a young child. Similarly, the caudal areas of CNS with more 
rudimentary functions contain more citrullinated MBP ( Nicholas et al 2003). 
Citrullination of MBP has been implicated in the pathomechanism of multiple sclerosis. (Gyorgy et 
al. 2006). 
 
Apoptosis 
PAD3 is among calcium-dependent molecules differentially regulated in response to spinal cord 
injury at stages of development permissive  (E11) and non-permissive (E15) for regeneration in 
chick embryos. Consistent with differences in up-regulation of PAD3 in spinal cord injured at E11 
and E15, more extensive citrullination was observed at the latter, non regenerative stage; by 24 
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hours, extensive citrullination as well as apoptosis and significant tissues loss is visible in injured 
E15 spinal cords (Fig 6 Fig7). The chick spinal cord can regenerate following injury until advanced 
developmental stages. It is conceivable that changes in stem/progenitor cell plasticity contribute to 
the loss of this capacity, which occurs around E13: increased proliferation in the grey matter and 
up-regulation of transitin expression following injury at E11, but not E15, suggested high levels of 
plasticity within the E11 spinal cord progenitor population that are lost by later stages. (Whalley et 
al. 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure7: Detection of apoptotic nuclei by TUNEL. 
From: “Changes in response to spinal cord injury 
with development:vascularisation, hemorrhage 
and apoptosis” ; Whalley et al. 2006 
(A-D) and Hoechst nuclear staining (E-F) in 
spinal cord injured at regeneration competent 
(E11), and incompetent (E15) stages of 
development.  A) E11 spinal cord injury (indicated 
by arrow), 24 hours after surgery: TUNEL positive 
cells (green) are located at the immediate injury 
site, but do not extend more than 500 mm cranial 
or caudal to the lesion. B) E11 spinal cord injury 3 
days after surgery: no positively labeled cells are 
present. The arrow points to the site of injury.  C) 
E15 spinal cord injury 24 hours after surgery: 
many TUNEL positive cells are present, extending 
for distances of several millimetres along the 
spinal cord. D) E15 spinal cord injury 4 days post 
lesion: TUNEL positive cells are still abundant 
within the cavity (asterisk) of the injured cord, and 
to a lesser extent in the surrounding regions.  E-F) 
E15 spinal cord injury 24 hours after surgery: 
examples of pycnotic nuclei (arrows) indicative of 
apoptotic cell death are shown at a high 
magnification.  Scale bars = 500 µm in A-C, 100 
µm in D, 1 µm in E-F. 
 
 
 Figure6 : analysis of  apoptosis after injury of E15 spinal cord.  Changes in progenitors populations and ongoing neurogenesis 
in the regenerating chick spinal cord; K Whalley et al. 2009A) H&E spinal cord 12 hours after injury and treatment with PBS. 
A’) Adjacent sections from the same spinal cord stained by TUNEL.  
 
   A 
   A’ 
 Fig6 : analysis of  apoptosis after injury of E15 spinal cord. From: “Changes in response to spinal cord injury with development:   
vascularisation, hemorrhage and apoptosis”; Whalley et al. 2006 A) H&E spinal cord 12 hours after injury and treatment with PBS. 
A’) Adjacent sections from the same spinal cord stained by TUNEL.  
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Intracellular calcium increase following neural damage plays a key role in secondary injury 
response. At non-regenerating stages treatment with calcium chelator after spinal cord injury, 
reduces apoptosis and cavitation of the chick spinal cord. (Lange et al; 2011 submitted). 
 Cl-amidine is a specific PAD inhibitor; following Cl-amidine treatments at the time of injury, 
secondary injury response in E15 spinal cord is greatly reduced with decreased apoptosis and cavity 
size.  
 
CITRULLINATION AND DISEASE 
 
Citrullination is also associated with several pathological conditions.  
 
Rheumatoid arthritis     
Rheumatoid arthritis is a chronic autoimmune disease characterised by symmetric inflammation of 
the peripheral synovial joints. Initially, the inflamed joints are painful and swollen and later, if not 
treated , the inflammation may lead to cartilage and bone destruction and could result in disability. 
The serum proteins and synovial fluid samples of patients with RA contain high concentration of 
autoantibodies against various targets as collagen type 2, aggrecan, heat shock proteins and some 
glycoproteins (Firestein, 2003) but these autoantibodies are not highly specific to RA. However, 
there are two autoantibody families that seem to be highly characteristic of the disease: Rheumatoid 
Factor (IgM antibody against human IgG Fc portion) and the family of anti-citrullinated protein 
antibodies (ACPA). Several experiments carried out by Masson-Bessiére et al., have identified the 
antigen recognised in the joints, by anti-keratin antibodies (AKA), anti-filaggrin antibodies (AFA) 
and APF (that belong to the ACPA family of antibodies),  as deiminated α and β chains of fibrin 
(Masson-Bessiére et al. 2001). Fibrin plaques are frequently found in the synovial tissue. Under 
physiological circumstances small amounts of fibrinogen (FBG) and other pro-coagulant proteins 
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can penetrate the capillary wall and travel to the interstitium, where they can be cleaved to fibrin 
peptides and fibrin monomers producing local plaques. These microplaques are then broken down 
by enzymes or may undergo endocytosis by macrophages. There is a sensitive balance between the 
presence and absence of fibrin molecules in the interstitium (balance of coagulation and 
fibrinolysis), which can be defective under pathological circumstances such as in RA. Citrullination 
appears to be the key element in shifting this balance. Polymerised fibrin is degraded by plasmin 
that cleaves near basic amino acid residues (Lys and Arg). The disappearance of the arginine by 
citrullination reduces the number of cleavage sites, hence increasing the quantity of polymer fibrin 
(Sebbag et al., 2004). Citrullination of antithrombin reduces its ability to inhibit thrombin, leading 
to a higher speed of coagulation (Chang et al., 2005). Citrullination of fibrin also renders the 
molecule antigenic, recognised by ACPA. The immune response results in increased plasma 
exudation and endothelial cell contraction. This in turn, increases the amount of FBG and other 
procoagulant protein in the interstitium (Rubin & Sonderstrup 2004). It has been suggested that 
smoking, vibration, exposure to mineral dust and injury increase the risck of developing RA (Aho 
& Heliovaara, 2004; Klareskog et al., 2006; Olsson, et al., 2004). These environmental effects often 
induce cell death, thus necrosis could possibly play a role in the aetiology of RA (Van Vernooij & 
Pruijn, 2000). During necrosis the integrity of the cell membrane is lost, and the cytoplasm 
containing enzymes like PAD, is released from the cell. The high interstitial concentration of Ca
2+  
can initiate the citrullination process. It has been shown that vimentin can be deiminated under these 
circumstances (Asaga et al., 1998). Its peptide fragments could be presented to T-helper cells by 
HLA molecules inducing a specific immune response (Hill et al., 2003). Synovial citrullinated 
proteins seem to be specific for RA and it has also been demonstrated that PAD2 expression is 
higher in RA joints then in controls and that both up-regulation of PADI2 gene and activation of 
PAD2 are important in the pathogenesis of RA (De Rycke et al., 2005). Recent studies suggest that 
citrullinated collagen types 1 and 2 are also target for ACPA (Burkhar et a., 2005; Suzuki et al., 
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2005). Citrullination of a self-antigen breaks immuno tolerance and collagen, as a key joint antigen, 
contributes to RA pathogenesis, because citrullinated forms of collagen type 2 increases 
immunogenicity and arthritogenecity. It was also shown that the severity of the arthritis correlates 
with PAD4 expression (in the infiltrating mononuclear cells) and with the amount of citrullinated 
collagen. Most importantly, it was also demonstrate that clinical signs of arthritis preceded the 
presence of citrullinated proteins and PAD4 expression. This strongly suggests that citrullination is 
more likely a consequence rather than a cause of joint inflammation. However, the pronounced 
antibody response against citrullinated joint antigens could contribute to the progression of the 
autoimmune inflammation. 
 
Multiple sclerosis 
Multiple sclerosis (MS) is a severe autoimmune disease that affects myelin sheaths in the CNS. The 
neurons of the CNS gradually lose their myelin sheat synthesised by oligodendroglial cells. As a 
result, electrical conduction is disturbed. The disease eventually causes paralysis and death. 
Citrullination plays a key role in the pathogenesis of  MS. Current knowledge attests that MS is 
caused mainly by overcitrullination of the MBP (Moscarello et al., 1994; Vossenaar et al., 2003; 
Wood et al., 1996). There is an increase in both the overall ratio of MBP-Cit/total MBP and the 
number citrullines within the MBP-Cit; in MS the brain resembles an ontogenetically earlier state, 
since young children have similar MBP-Cit/total ratios. Citrullination reduces the positive charge of 
the protein, lowering its affinity to the negatively charged myelin phospatidyl-serine residues. It has 
been shown in vitro that the amount of citrulline residues in MBP negatively correlates with its 
lipid-aggregating ability (Mastronardi et al., 1996; Wood & Moscarello, 1989). Cathepsin D can 
degrade MBP more easily if it is citrullinated, as MBP-Cit has a more open structure (Pritzker et al., 
2000). The protease can release an immunodominant peptide, the 
44
Phe-Phe
89 
peptide, and this way 
an autoimmune response can be elicited (Whitaker at al., 1980). Lymphocytes and other immune 
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cells infiltrate the nervous tissue and cause local inflammation, oxidative stress and nerve cell death 
or myelin sheath destruction.  
Pritzker et al. proposed a mechanism for the increased citrullination in MS patients, claiming that 
methylation affects citrullination (Pritzker et al., 2000). MBP is a methylated protein, and if it is not 
methylated, no myelin sheath is formed. Methylation increases the hydrophobicity of MBP and 
reduces its ability to become citrullinated, as methylated MBP has a more condense structure then 
the unmodified version. It could be speculated that a reduced methyltransferase activity is 
responsible for the enhanced citrullination of MBP in MS. GFAP (glial fibrillary acid protein), an 
astrocyte-specific intermediate filament, also undergoes deimination. Nicholas et al., suggested that 
GFAP could be overcitrullinated in MS (Nicholas et al., 2004) and supported the hypothesis that 
citrullination plays a cardinal role in the development of MS. 
As citrullination seems to be a key process in MS, a PAD2 inhibitor therapy trial is currently 
underway. A cytotoxic, chemotherapeutic taxol derivative, paclitaxel inhibits human PAD2 in vivo 
and in vitro (Pritzker & Moscarello, 1998). Administering  paclitaxel to DM-20 mice, the 
demyelinisation process slows down and the CNS symptoms abate (Moscarello et al., 2002). Not 
only enhanced citrullination of myelin
 
basic protein contributes to destabilization of the myelin 
membrane
 
in the CNS of multiple sclerosis (MS) patients: it has been recently  report
 
increased 
citrullination of nucleosomal histones by PAD4 in
 
normal-appearing white matter (NAWM) of MS 
patients and in animal
 
models of demyelination. Histone citrullination was attributable
 
to increased 
levels and activity of nuclear PAD4. PAD4 translocation into the nucleus is attributable to elevated 
tumor nercrosis factor- (TNF) proteins which may derive from
 
astrocytes. In cell cultures of mouse 
and human oligodendroglial
 
cell lines, PAD4 is predominantly cytosolic but TNF- treatment 
induces its nuclear translocation. Several experiments carried out on transgenic mice show that high 
citrullination of histones, consequent to PAD4 nuclear translocation is part of the process that leads 
to irreversible changes in oligodendrocytes and may contribute to apoptosis of oligodendrocytes in 
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MS (Increased Citrullination of Histone H3 in Multiple Sclerosis Brain and Animal Models of 
Demyelination: A Role for Tumor Necrosis Factor-Induced Peptidylarginine Deiminase 4 
Translocation ; Mastronardi et al., 2006). 
 
Alzheimer’s disease 
A recent report claims that patients with Alzheimer’s disease (AD) have significantly elevated  rate 
of citrullination in their CNS, mainly in the hippocampus, which is the region of the brain most 
affected by the disease (Ishigami et al., 2005). Comparison of data from patients with AD with 
those obtained from control individuals has revealed that it was increased in the patients. One can 
hypothesise that during neurodegeneration a higher concentration of Ca
2+ 
activates the citrullination 
process. The predominant over-citrullinated  proteins include vimentin, MBP and GFAP. 
 
Psoriasis 
This disease is characteristic by an enormous mitotic activity  in the human epidermis and the rapid 
cell proliferation results in abnormal cornification. Typical symptoms are itching, sensitivity of 
affected skin and the presence of red patches covered with silvery-white scales of dead skin. 
Citrullination is implicated in the phatomchanism of psoriasis, however the exact mechanism is 
unknown. Cytokeratin K1 has been shown to contain reduced amount of cytrullyl residues in the 
psoriatic epidermis (Ishida-Yamamoto et al., 2000). Interestingly, in a recent phase 2 pilot trial the 
PAD2 inhibitor paclitaxel (also implicated as a therapeutic agent in MS) has been demonstrated to 
have therapeutic activity in patients with severe psoriasis (Ehrlich et al., 2004). 
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Peptidylarginine deiminase of a pathogen potential virulence factor 
Peptidylarginine deiminases are ancient enzymes that developed early in evolution (Vossenaar et 
al., 2003). This has been verified by the identification of a prokaryote PAD enzyme in 
Porphyromonas gingivalis (McGraw et al., 1999). This enzyme shows little sequence similarly to 
the human PAD enzymes, however, it can efficiently deiminate either peptidyl arginine or soluble 
arginine substrates (in a Ca
2+ 
-independent manner). The enzyme plays a key role in the 
pathogenesis of periodontitis, a common disease caused by this bacterium (McGraw et al., 1999). 
During Arg conversion, ammonia is produced that contributes to the neutralisation of the local pH. 
The enzyme can inactivate anaphylatoxins, produced locally during complement activation, or by 
the cleavage of C5 by the bacterial RGPs protease (Wingrove et al., 1992). It can inactivate 
bradikinine and can regulate plasma-outflow (Imamura et al., 1994). It can also inactivate special 
anti-adhesive molecules produced by the host.  For these reasons, bacterial PAD could be regarded 
as a potential virulence factor. 
 
Tumors 
Recently it has been found a relationship between PADI expression and certain tumors. 
Immunohistochemistry indicates that PAD4 had significant expression in many tumor tissues, 
especially various adenocarcinoma. Western blotting with anti PAD4 antibody and immunostaining 
with anti citrulline antibody confirm the expression of the enzyme in these tumor. Mostly, PAD4 
seems to contribute to the disrupted apoptosis of tumors by caspase-mediated cleavage of 
cytokeratin, CK. Another important finding comes from double immunofluorescent labeling which 
detected co-location of PAD4  with CD34, a cell marker of heamatopoietic progenitor cells (HPC) 
in bone marrow and other normal tissues, as well as in some fibroblast-like cells at stroma region of 
tumors tissues. Because there are more CD34+ cells expressing PADI4 in tumour tissues then in 
normal tissues it is postulated that the development of PADI4-expressing tumour cells may be 
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associated with the abnormal proliferation of CD34+ stem cells or their progeny. (Chang et Han, 
2006; Chang et Fang 2010). A work carried out from Wang et al. in 2010 suggests also an 
important role for PADI4 in ovarian cancer tumorigenesis that is under the regulation of estrogen. 
Not only PAD4 but also PAD2 is found in several tumors such as breast (mammary gland) tumor, 
colorectal tumor, gastrointestinal tumor, glioma, head and neck tumor, leukemia, ovarian tumor, 
pancreatic tumor, prostate cancer, skin tumor, soft tissue/muscle tissue tumor (data from Genes to 
System Breast Cancer Database, G2SBCD). 
Neuroblastoma is the most common extracranial solid cancer in childhood and the most common 
cancer in infancy, with an annual incidence of about 650 new cases per year in the US. It is a 
neuroendocrine tumor, arising from any neural crest element of the sympathetic ganglia of the 
paraspinal region or the adrenal gland. Neuroblastoma in children under 5 years presents in the 
abdominal region and in infants under 1 year of age has an high incidence in the thoracic region. 
The most widely characterized cytogenetic alterations in neuroblastoma tumors,  include the loss or 
rearrangement of the distal portion of the short arm of chromosome 1 (1p31-term) and amplification 
of the N-myc gene (Thiele, 1998) . Many neuroblastoma cell lines has been created to allow studies 
on protein expression and mRNA analysis. LAN5 cells belong to such neuroblastoma cell lines and 
as they comes from embryonic child tumor, I used LAN5 cell line in my project to investigate if 
there is a  relationship between neural embryonic stem/progenitor-derived tumor and PADI 
expression like what found for PAD4 and CD34+ stem cells (Chang et Han, 2006; Chang et Fang, 
2010). 
 
 
At present  it is hypothesised a two-regulation  model for PADs: at an extremely high concentration 
of Ca
2+ 
PAD is fully active and may lose substrate specificity; this could also happen 
extracellularly, if the concentration of  Ca
2+ 
were high enough. There may be a physiological 
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regulatory mechanism at low concentration of Ca
2+ 
, possibly mediated by other proteins or PAD 
protein interactions; when PAD is active at a low-level of Ca
2+ 
, it has the higher substrate- and 
arginine-specificity . At high level of  Ca
2+ 
, PAD can deiminate nearly any arginines of any 
proteins. This could lead to autoimmunity, since the highly variable deiminated proteins (in which 
arginines are citrullinated), may be recognised as neoantigens by the immune system.  
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OBJECTIVES 
 
A number of calcium-dependent mediators of apoptosis are known to be activated in response to 
injury and contribute to secondary injury response. The screening carried out in the chick spinal 
cord has identified PAD3 as one of these factor (Lange et al; 2011 submitted).  
Recent experiments on chick spinal cord show that  extensive apoptosis and cavitation, rapid 
increase in citrullination  and PAD3 up-regulation as consequences of  treatment with thapsigargine 
(chemical able to rise cytosolic calcium concentrations). An earlier treatment with Cl-amidine can 
reduce the effects of thapsigargine with less apoptosis and cavitation then the control and that 
supports a putative role of PADs and citrullination during apoptosis, as indicated by the results 
following PAD inhibition. Because of PADs have been implicated in a number of 
neurodegenerative diseases, the identification of the role of PAD and the possibility of inhibiting its 
activity pharmacolgically may be important for the development of cures to reduce damage in 
humans. 
As first aim of my project I investigated on the possibility to model the injury response in neural 
cells in vitro to eventually establish a model for studying PAD, citrullination and injury response in 
human neural cells. Secondly I tried to better characterize expression pattern and possible role(s) of 
PAD, focusing mainly on PAD3, during neuronal differentiation first and then in neural cell death 
and survival; the experiments were carried out initially using neural progenitor cells derived from 
E7 (embryonic day 7) chick midbrain (cMB cells), which were shown to express PAD3 both at the 
protein and mRNA level (Lange et al; 2011 submitted), and subsequently in a human neural tumor 
cell line, the neuroblastoma cell line LAN5. To this purposes my experiments focused on PAD3 
protein and transcript, on β3-Tubulin expression and on CitH3 amount ,as histone3 has been shown 
to be the nuclear target of PAD (Li et al. 2010; Mastronardi et al., 2006). 
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MATERIALS AND METHODS 
 
I chose to work in chick cells from embryos at day7 because that is a good stage to collect enough 
tissue which is easier to dissect then younger embryos but still with a large neural precursor 
population. 
As qualitative approach I set up immunostainings and observed the results on fluorescent 
microscope, while the quantification of the levels of Cit-H3 and β-3 tubulin has been performed by 
western blot. In the first experiments I tried to asses a possible relationship between PAD3 activity 
and neuronal development and differentiation. To this purposes PAD3 protein and β3-Tubulin 
expression have been studied at the same time by double immunostainings in cells kept in both 
proliferating and neuronal differentiating medium, while by PCR I analyzed Pad3 transcript in 
different tissues during chick embryonic development. 
The second part of the experiments done, started with the study on the possibility to model the 
injury response in neural cells in vitro. I first studied the effects of PAD inhibition, using Cl-
amidine, and PAD activation, using thapsigargine to raise intracellular calcium, on cell survival, 
and then on expression and cellular localization of PAD and on citrullination of histone 3 (H3) in 
cMB cells. In some experiments chick midbrain cells from E7 embryos were treated also with the 
p53 inhibitor, pifithrin, to assess whether p53 is required for PAD activity. 
 
As first step I made dose-dependent curves to choose among different concentrations of Cl-amidine 
and thapsigargine the highest non-toxic one, and growth-assays for different pifithrin doses. 
Pifithrin is an inhibitor of p53 which has been used to see if the activity of PAD in chick MB cells 
could be dependent by p53 interaction, according to what has been shown for PAD4 in mice, or not 
( Li et al., 2010). 
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Once the dose of each chemical has been chosen, I decided to use qualitative and quantitative 
approaches trying to figure out if those treatments gave differences in PAD3, b-3 tubulin and Cit-
H3 amount in chick midbrain cells. As the results obtained excluded a role of PAD3 in cell 
differentiation, I studied if PAD3 may have an effect during apoptosis and senescence. To 
investigate whether expression of PAD3 and CitH3 amount may change with time in culture, PAD3 
and CitH3 localization and response to the treatment was investigated also in chick cells at passage 
30 (P30) as cMB cells were found to become senescent and die around P30. 
As certain tumor cell lines were reported to express PADs, I assessed expression of PAD3 and 
PAD4, another PAD that can localize to the nucleus, and the response to thapsigargine and Cl-
amidine treatment in human neuroblastoma cells, LAN5 . 
 
In the experiments carried out I focused the attention only on PAD3 in chick midbrain cells, 
because this is the only PAD enzyme found in chick nervous system till now , and for PAD3 and 
PAD4 in LAN5 cells because in human cells these show nuclear localization.   
I set up PCR both on chick cells and tissues and on LAN5 cells to check if these enzymes (PAD3 in 
chick, PADI1-4 in human) are really expressed (as results in previous western blot) and if there is a 
difference in the pattern of PAD3 expression during development and cell differentiation: to this 
purpose chick embryos in different stages were collected and dissected to isolate skin and different 
parts from the nervous system and PCR for Pad3 transcript has been repeated several times, trying 
to optimize the conditions of reaction for results as clear as possible. 
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1   Cell cultures and media 
 
1.1 Chicken midbrain cells : 
Chick midbrain cells from embryos in day 7 were grown in flasks in proliferating medium at 5% 
CO2 and 37°C as conditions of incubation. Trying to push these cells into neuronal differentiation a 
differentiating medium has been used as well. 
 
1.2   Proliferating medium:  
10% FBS ( fetal bovine serum), 5% HS (horse serum), 1% penicillin-streptomicine, 1% glutamine  
in high glucose DMEM ( Dulbecco’s modified eagle medium). 
 
1.3  Differentiating medium:  
1% N2 , 1% penicillin-streptomicin, 1% glutamine in NeurobasalA medium. Cells were kept 
differentiating minimum 3 days before doing the western blot analysis on β3-Tubulin amount. 
 
1.4  LAN5 cells: 
LAN5 cells are Neuroblastoma cell line characterized by cytogenetic alterations, including the loss 
or rearrangement of the distal portion of the short arm of chromosome 1 (1p31-term) and 
amplification of the N-myc gene. LAN5 cells are morphologically small, neuroblastic shaped and 
grow in cell aggregates. ( Neuroblastoma Cell Lines, Thiele 1998 ). They have been grown in 
Neuroblastoma proliferating medium at 5% CO2  and 37°C. 
 
Neuroblastoma proliferating medium: 10% FBS, 1% penicillin-streptomicin, 1% glutamine in 
MEME (minimum essential medium eagle). 
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2  Cell passaging 
 
Both cell cultures were split in new flasks containing fresh medium every time they reached 70% of 
confluence. This work has been done under antiseptic condition using laminar flow hood. After 
aspirating medium and the dead-floating cells with a glass pipette, cells attached on the flask 
surface has been washed 1 minute in 10x PBS. PBS has been aspirated and 1 ml ( T-25 cm
2 
flasks) 
or 2 ml thripsin ( T-75 cm
2
 flasks) added and left for 1 min at 37° C at 5% CO2 . 
Thripsin has been neutralized adding 4 ml ( T-25 cm
2 
flasks)  or 8 ml ( T-75 cm
2
 flasks) of 
proliferating medium , and detached cells have been harvested by aspiration of the mixture  medium 
+  thripsin. The harvested suspension has been placed in plastics tubes and spin out  5 min at 1000 
rpm. Centrifugation share 2 phases: one pellet on the bottom of the tube and the supernatant on the 
top. Cells were harvested by aspirating the surnatant and resuspending the pellet in 1 ml of 
proliferative medium. Living cells concentration has been calculate by counting on emocytometer 
in which we transferred 10 μL of a solution consisting in 10 μL cell suspension and 90 μL trypan 
blue. About 1x10
5 
cells were plated in T-75 cm
2
 flask containing10 ml of medium. 
 
 
3   Treatments 
 
 
3.1  Cl-amidine 
Cl-amidine ( N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide ) is a specific irreversible 
time and concentration dependent inactivator of PAD; it is the most potent PAD inhibitor.  
Mechanism of inactivation: binding of calcium to PAD triggers a conformational change that moves 
a Cys645 into a position that is competent for catalysis; thus, if Cl-amidine reacts with an active site 
residue, it preferentially inactives the calcium-bound form of the enzyme by > 10-fold.  The 
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Inhibitory properties of Cl-amidine-mediated inhibition : calcium-dependent inactivation and 
irreversible nature of the enzyme-Cl-amidine complex. 
The rate constants for the inactivation process KI, KINACT, KI / KINACT  have been calculated using 
the following non-linear progression curves: 
[ Cit ] = vi ( 1-e 
Kobs^t 
) Kobs 
 
where vi is the initial velocity, Kobs is the apparent pseudo-first-order rate constant for inactivation 
and [ Cit ] refers to the concentration of citrullination produced during the time course. By plotting 
Kobs versus [ Cl-amidine ] values for KINACT ( 2,4 +/- 0,2 min
-1 
) and KI ( 180 +/- 33μM ) are 
determinated, and the second-order rate constant , results to be KINACT / KI = 13000 M
-1  
min
-1
. 
(Y. Luo et al.,2006  , Y. Luo et al. 2008” ). 
 
3.2   
 
 
Figure8: Two potential mechanisms of PAD inactivation. Mechanism 1 involves direct substitution of the halide, 
whereas mechanism 2 involves the formation of a tetrahedral intermediate, which first evolves into a three-membered 
sulfonium ring and subsequently rearranges to the thioether with the collapse of the tetrahedral intermediate. The 
letter mechanism is invoked to account for the poor leaving group potential of chloride or fluoride. From:” Inhibitors 
and inactivators of protein argine deiminase 4: functional and structural”, Luo . et al.,2006) 
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3.2  Thapsigargine 
Is a non-competitive inhibitor of a class of enzymes known by the acronym SERCA, which stands 
for sarcoplasmic and endoplasmic reticulum Ca
2+ 
ATPase. It is structurally classified as a 
sesquiterpene lactone and is a tumor promoter in mammalian cells. Thapsigargine raises cytosolic 
calcium concentration by blocking the ability of the cell to pump calcium into the sarcoplasmic and 
endoplasmic reticula which causes these stores to become depleted. Store-depletion can secondarily 
activate plasma membrane calcium channels, allowing an influx of calcium into the cytosol. 
Thapsigargine acts through inhibition of the endoplasmic reticulum calcium pump by recognition 
and interaction with a site found in all of the known intracellular-type calcium pumps (SERCA1, 
SERCA2a, SERCA2b, SERCA3). ( Lytton et al. 1991). 
 
 
Figure 9: molecular structure of thapsigargine. From website: http://en.wikipedia.org/wiki/Thapsigargin 
 
 
3.3  Pifithrin 
Pifithrin (chemical name 2-(2-imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolyethenone 
hydrobromide) is a chemical inhibitor of p53. It is soluble in DMSO up to 20mg/mL. It is a 
reversible inhibitor of p53-mediated apoptosis and p53-dependent gene transcription such as cyclin 
G, p21/waf1, and mdm2 expression, and for this reason pifithrin is the lead compound for a novel 
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group of small molecules that are being developed for use as anticancer agents.  Pifithrin inhibits 
p53-dependent apoptosis through an undeterminated mechanism. ( Hoagland et al., 2005). 
 
 
Figure 10: molecular structure of pifithrin. From website http://en.wikipedia.org/wiki/Pifithrin 
 
 
4    Chick embryos collection 
 
 
Fertilized Leghorn eggs (Needle Farm, Cambridge, UK) were incubated at 37°C in a humidified 
forced flow incubator. Before incubation a small hole was made in the shell to create a window by 
which check chick embryos growth. All the procedures were approved under the Animals Scientific 
Procedures Act 1986.  
At E3, E5, E7, E11, E13 and E15 stages a pair of fine forceps was used to make a small hole in the 
chorioallantonic membrane, carefully avoid major blood vessels. A glass hook, prepared by heating 
and bending a glass pipette, was pushed through the hole and used to lift the embryo gently towards 
the window. E5, E11 and E15 embryos were transferred in a Petri dish containing 1X PBS. 
Working under stereomicroscope brain and spinal cord were carefully dissected from E5 embryo 
using fine forceps and a needle, and the same protocol has been used to dissect forebrain, midbrain, 
hindbrain, spinal cord and skin from E11, and E15 embryos. Each sample was quickly stored in 
eppendorf tube at -80°C until it was needed for protein and mRNA extraction. 
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The whole E3 and E7 embryos were stored at -80°C without previous dissection. 
 
 
5    RNA analysis:  Extraction and Reverse Transcription 
 
 
RT-PCR was used to study Pad3 gene expression in chick cells at different developmental stages , 
Pad3 transcript in chick MBcells with aging, and in LAN5 cells PADI1-4 and p21 expression 
(keratinocytes used as human positive control). 
 
 
5.1  RNA extraction 
 
Total mRNA was extracted from each tissue, from LAN5 cells and from chick following the 
protocol of INVITROGEN life technologies: 
1. tissues from E5, E11, E15 and the whole E3 and E7 embryos and the sample pellets 
from culturing were homogenized/ resuspended in 1 mL of TRIZOL ; 
2. incubation  of the homogenized samples for 5 minutes at room temperature to permit the 
complete dissociation of nucleoprotein complex; 
3. adding 0,2 ml of chloroform per 1 ml of TRIZOL reagent. Tubes were shacked 
vigorously by hand for 15 seconds and incubated at 15 room temperature for 2 minutes. 
4. centrifugation at 12000 x g for 15 minutes at 4 °C; 
5. the aqueous phase was transferred to a fresh tube and mixed with 0,5ml of isopropyl 
alcohol to precipitate the RNA. 
6. incubation of the samples for 10 minutes at 15 to 30°C and centrifugation at 12000 x g 
for 10 minutes at 4 °C; 
7. RNA precipitate formed a gel-like pellet on the side and bottom of the tube. The 
supernatant was removed and the RNA pellet washed adding 1ml of 75% ethanol. 
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8. centrifugation at 7500 x g for 5 minutes at 4 °C. 
9. drying of RNA pellet and resuspention in 30 μL of milliQ water RNAse free. 
 
5.2     RNA quantification 
mRNA quantification was performed using NanoDrop Spectrophotometer (ND-1000) and the ND-
1000 software. 2 μL aliquots of RNA were assessed for concentration and ratio (260/280) to check 
the quality of the samples. Following RNA quantification, aliquots of 1 μg RNA were made, 
transferred in new microtubes and stored at -80°C. 
 
5.3   Reverse Transcription 
For real time PCR, cDNA was produced in 20 μL from 1 μg of total RNA using the following 
protocol: 
1      μg of RNA was mixed with 1 μl of random examer primers. 
2.      incubation for 10 minutes at 70°C, using program 58 set on the PCR machine. 
3.    4 μl MLV-RT buffer, 2 μl dntp (10 microM), 1 μl MLV-RT enzyme, 1 μl RNA inhibitor  
and water RNAse-free were added to the RNA+ random examer primers samples in 20 μL of 
final volume. 
4.      reagents were mixed by vortex; 
4    incubation for 1 hour at 42°C first and then for 10 minutes at 95°C 
5    the resulting cDNA was stored at  -80°C. 
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6     Real Time PCR 
 
6.1    Primers designing 
Chick’s Pad3 primer sequences were designed using Primer3 Output and BLAST softwares, and 
NCBI and Quantitative PCR Primer Databases. 
As primers for human PAD1, PAD2, PAD3, PAD4 , p21 and GHDPH were used sequences 
published in the recent scientific article (Méchin et al., 2010).  
 
The table below shows the primer sequences we used and the amplicon size. 
 
Gene  Specie Forward primer sequence Reverse primer sequence Exon/s 
Product 
size 
Annealing 
Temp  
PAD1 human 5’–cgccatcctctctgccctcttgcta-3’ 5'–ggtttttctgtccttgtttgtccac–3' 16 3'-UTR 571 bp 58 
PAD2 human 5’–atgcaccttcatcgacgacattt–3’ 5’–tttcagcagggacagagtcgag–3’ 16 332 bp 54 
PAD3 human 5’–cagagacaggcccctgaacgataa–3’ 5’–aagatggttccgccctgatctaa-3' 16 3'-UTR 483 bp 54 
PAD3 human  5’-gcagagtgtgacatcattgacatcc-3’ 5’-gaccgcaccttctcctccag-3’  -  167bp   57  
PAD4 human 5’–tcttgtgaatattgtggctccct–3’ 5’–agagcagaactgagtgtgcagtg–3’ 16- 3'-UTR 134 bp 56 
GDPH human 5'-ccttcattgacctcaactacatggt-3' 5'-ctaagcagttggtggtgcaggt-3' - 488 bp 60 
p21 human 5'-ctgggtgtgagccctgcgtg-3' 5'-tgaggcacagcgagccaacg-3'  - 187 bp         57 
Pad3 
Gallus 
gallus 
5’ -ctccagcctcgactccttc- 3’ 5’- gcagccagtctgagaagagc- 3’ 11-12 198 bp  55  
Gdph 
Gallus 
gallus 
5'-ccaggttgtctcctgtgact-3' 5'-cacaacacggttgctatatc-3' 12-13 158 bp 55 
 
Table1: primer sequences, annealing temperatures, products size 
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6.2   Real Time PCR 
For each pair of primers I made a PCR solution consisting in 0,1 µL of Biotaq enzyme, 0,75 µL 
MgCl, 2 µL Buffer-Taq, 1 µL cDNA, 12,5 µL H20, 1 µL primer F, 1 µL primer R and 2 µL dntp in 
20 µL total volume.  
As there are differences in GC content, melting temperature Tm, length (number of nucleotides) and 
specificity on the target sequences between couple of primers, all PCR reactions have been run 
separately in different eppendorf tubes and  the optimal reaction conditions for each kind of PCR 
have been studied and used.  
 
6.3    Agarose Electrophoresis 
Agarose electrophoresis was performed to visualize PCR products. This step allowed to determine 
if  the mRNA previously reverse-transcripted and amplified, of a specific gene,  was expressed in 
the cells of interest and if the resulting PCR products  had the correct size.1% Agarose Gel was 
made in a glass becker by mixing 1,0 g of agarose in 100 ml TAE Buffer 1X (solution of Tris base, 
Glacial Acetic Acid and EDTA in distilled water). Agarose powder was melted in TEA by warming 
up the solution from 1 to 2 minutes in a microwave and after a rapid cooling of the solution by 
placing the becker under cold running water, 5 μL EtBr (Etidium Bromide) were added. The 
solution was then poured into gel tray pre-assembled into a casting chamber and  the casting comb 
was placed in the appropriate slot. The gel was let sit 30 minutes until it became cool to touch and 
opaque in appearance and then completely wet with Running Buffer (solution of bromophenol blue 
orxylen cyanol, sucrose and water). Samples of cDNA kept in ice, were weighted by adding 5 μL 
Loading Buffer (solution of 30% w/v sucrose, Orange G and distilled water)  and then carefully 
loaded in the wells after removing the comb from the solidified agarose gel. 5 μL Ladder were 
loaded in the first well.  After loading, cDNA were run by the application of a constant current of 
120 mV. The gel was placed under UV rays in a UV chamber to visualize PCR product 
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7    Growth assays  
 
Before using the treatments previously described it has been necessary to choose the highest-non 
toxic concentration for each one. To this purpose several doses of  thapsigargine and Cl-amidine has 
been tested by methylene blue assay which indicates the effect of each dose on cell survival. The 
concentration of pifithrin has been chosen by using a different approach, checking not only cell 
survival (as in methylene blue assay) but also cell proliferation by time-laspe microscopy. On the 
base of the results found the concentrations chosen were: 20 μM for pifithrin, 10 μM for 
thapsigargine,  and 200μM for Cl-amidine. 
 
7.1    Methylene Blue Assay 
 
The methylene blue assay was adapted from that described in Oliver (1989). After culturing in 96 
well plates chick cells from midbrain of embryo in stage 7, thapsigargine and Cl-amidine were 
added in different concentrations in cell mediums and the sample were stored at 4°C overnight. 
Three reply have been done for each concentration. The day after, cell mediums were drained using 
a multichannel pipette and each well fixed with 100μL of 4% PFA in 0,15 sodium chloride for 30 
minutes. Fixative was removed by a prorating flick of the wrist into a sink and the surface of the 
plate inverted and patted dry with a towel. 100μL of methylene blue solution was added to each of 
the previously fixed wells for 30 minutes. The dye was removed by a prorating flick of the wrist as 
described before. The plate was placed upside down on a paper towel to remove the methylene blue. 
Excess methylene blue in each well was washed with 200μL of 0,01 M borate buffer by filling from 
left to right with a multichannel pipette, before licking into the sink as described previously. The 
second wash was performed by filling from right to left, to ensure that the washing time per well 
was the same on average. The first and second washes were repeated. The plate were then immersed 
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in a tank of 0,01 M borate buffer and contents flicked out as before. The methylene blue that had 
stained the cells was extracted by adding a 100μL mixture of 50% ethanol and 50% 0,1 M HCl to 
each well. 
Wells were shaken gently and absorbance at 650 nm (A650) measured in each well with a microplate 
reader (Revelation v4.21, Dynex Technologies) and the background from empty wells subtracted. 
Samples were left for 1 to 2 hours at room temperature before measurements to allow most of the 
dye to exit the cells. 
Thapsigargine-toxicity was assessed in proliferating medium while Cl-amidine was assessed both in 
proliferating and differentiating medium. 
 
The table shows the concentration tested for both chemicals. 
 
 
Thapsigargine 0,25 0,5 1 2,5 10 
Cl-amidine 25 50 100 200 / 
 
Table2: concentration of thapsigargine and Cl-amidine tested by methylen blue assay 
 
 
7.2   Time-lapse analysis after pifithrin treatment 
 
Pifithrin is a chemical which inhibit p53. It was used to study if the activity of PAD in chick cells 
depends to p53-PAD interaction, as what has been shown for PAD4 in mice. (Li et al.,2010). 
Pifithrin speeds up cell growth by inhibition of p53 promoting tumors; for this reason different 
doses of this chemical were assessed on chick cells, looking for the highest not-toxic and not-
tumorigenic concentration. 
                   Concentration (μM ) 
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After culturing chick midbrain cells (E7) in 24 well plate, cells were treated with different 
concentration of  20 mg/mL pfithrin in DMSO, other cells were treated with 0,2% DMSO (1 μl 
DMSO in culturing medium which parallels to the highest volume of pifithrin used on cells ) or 
remained untreated to have negative controls and to share effects of pifithrin to the ones due to 
DMSO only. The sample were incubated at 37°C and checked after 6 hour from the treatment. 
The table shows the concentration of pifithrin tested: 
 
 
 
 
 
Pfithrin 10 15 20 50 100 
 
       Table3: Concentration of pifithrin tested by proliferation check 
 
 
 
8     Cell death and survival 
 
Chick cells have been grown 3 days in T-25 flask in proliferating and differentiating medium before 
adding 20 μM pifithrin, 10 μM thapsigargine,  200μM Cl-amidine, and 200μM Cl-amidine + 10 μM 
thapsigargine to each flask ( 3 flasks per treatment). Treatment were left acting on cells for 24 hours 
and then cells were checked by time lapse microscope to study if PAD3 activation with 
thapsigargine increases cell death and if a pre-treatment with Cl-amidine  ( PAD inhibition) protects 
cells from apoptosis  as what observed during spinal cord injury in vivo. We tried then to keep each 
treatment for longer.  Cells treated for 20 hours were collected and then western blot was performed 
to study if these drugs could change β-3 Tubulin levels in chick cells suggesting a role of PAD3 
during neuronal differentiation. 
                   Concentration (μM ) 
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9   Immunocytochemistry 
 
Expression of β-3 Tubulin neuronal marker and PAD3, were analyzed in chick cells from midbrain 
of E7 stage and in 22 passage (P22). Expression and distribution of PAD3 has been compared 
between chick cells kept in proliferating medium and chick cells that were going through neuronal 
differentiation. As the aim of this experiment was to asses a possible relationship between PAD3 
activity and neuronal development and differentiation, β-3 Tubulin expression has been observed at 
the same time. 
Expression and localization of PAD3 its nuclear target CitH3 in chick neural cells was then studied, 
after treatment with 10μM Thapsigargin, 200 μM Cl-amidine and both drugs together comparing 
the results with the untreated samples. Thapsigargine and Cl-amidine treatments were used also on 
LAN5 cells (human Neuroblastoma cells) to study the expression of CitH3, PAD2, PAD3 and 
PAD4 s and the effects of these chemicals in this kind of tumor cells. These treatments were done 
on chick and LAN5 cells 70% confluent and  the effect of treatment was assessed  on after 2 hours 
in incubation at 37 ° C. In the samples used to study the effects of thapsigargine and Cl-amidine 
together, Cl-amidine was added first and kept in incubation for 15 minutes and after that we added 
thapsigargine: this approach was thought to be useful to share PAD activity from the effects of other 
Ca
2+
-dependent enzymes, by inhibiting PAD and activating all the other Ca
2+
-dependent enzymes at 
the same time. 
 
 
10.1   Immunofluorescent stainings 
Cells grown on glass coverslip in 24-well plate were drained by aspirating the medium using a 
200μL- tip pipette and then washed three times for 10 min in PBS (phosphate-buffered saline) 1X.  
Each well was fixed with 500 μL 4% PFA for 15 minutes. Fixative was removed with three 10 
minutes PBS washes and samples were blocked for 45 minutes in 350 μL of  blocking solution with 
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0,5 % Triton-X.  Coverslips were transferred in a humidified chamber and the blocking solution 
was replaced with the primary antibody/es  diluted in blocking solution;  primary antibody/es were 
kept overnight at 4°C. The day after, primary Ab in excess were removed by three 10 minutes PBS 
washes, followed by incubation for 1 hour in the dark with Hoescht dye and flurochrome 
conjugated secondary antibodies. After the last three 10 minutes washes in PBS, the coverslips were 
mounted onto slides with a drop of Citifluor
TM 
per coverslip. 
The edges were dried with a clean tissue, sealed with nail varnish and kept in the dark at 4°C. 
Immunofluorescence was observed by using fluorescent microscope. 
 
 
10.2    Summary of Antibodies and conditions  
 
Table4: summary of antibodies and conditions of reaction. 
1ry Ab 1ry Dilution Origin 2ry Ab 2ry Dilution 
Tuj1 1/1000 Mouse Goat Anti-Mouse 488 1/400 
PAD3 1/200 Rabbit Goat Anti-Rabbit 594 1/400 
PAD3 1/200 Rabbit Goat Anti-Rabbit 488 1/400 
PAD4 1/200 Rabbit Goat Anti-Rabbit 488 1/400 
CitH3 1/250 Rabbit Goat Anti-Rabbit 488 1/400 
                         
Abbreviations: 1ry Ab= primary antibody; 2ry Ab= secondary antibody 
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The table below shows the combinations of primary and secondary Ab used and the treatments done in each experiment: 
 
 
 
Cells Medium Treatments 1ry Antibody/es solution 2ry Antibody/es solution 
Chick proliferating / 1/1000 Tuj1 + 1/200 PAD3 in 50 μL block. 1/400 anti-M 488 + 1/400 anti-R 594 + 1/400 Hoescht in 50 μL block 
Chick differentiating / 1/1000 Tuj1 + 1/200 PAD3 in 50 μL block. 1/400 anti-M 488 + 1/400 anti-R 594 + 1/400 Hoescht in 50 μL block 
Chick proliferating Thapsigargine, Cl-amidine 1/200 PAD3 in 50 μL block. 1/400 anti-R 488 + 1/400 Hoescht in 50 μL block 
Chick proliferating Thapsigargine, Cl-amidine 1/250 CitH3 in 50 L μL block. 1/400 anti-R 488 + 1/400 Hoescht in 50 μL block 
LAN5 lan5 medium Thapsigargine, Cl-amidine 1/200 PAD3 in 50μ L block 1/400 anti-R 488 + 1/400 Hoescht in 50 μL block 
LAN5 lan5 medium Thapsigargine, Cl-amidine 1/200 PAD4 in 50 μL block 1/400 anti-R 488 + 1/400 Hoescht in 50 μL block 
LAN5 lan5 medium Thapsigargine, Cl-amidine 1/250 CitH3 in 50 μL block 1/400 anti-R 488 + 1/400 Hoescht in 50μ L block 
 
 
 
Table5: combinations of primary and secondary Ab used and the treatments done in each immunostaining
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10     Western Blotting 
 
 
               This approach was used to study eventual differences in the amount of β3-Tubulin protein in chick 
MB cells at passage 14 (P14) according to the different treatment done on cells (pifithrin, 
thapsigargine, Cl-amidine , thapsigargine + Cl-amidine) grown both in proliferating and 
differentiating medium. Western blot was performed also to analyse differences in CitH3 amount, 
both in chick and LAN5 cells, using the same treatments. 
 
10.1   Protein extraction 
Proteins were obtained by homogenizing chick midbrain cell pellets from passage 12 (P12), passage 
14 (P14)  and passage 30 (P30)  and LAN5 pellets in 50μL ice-cold RIPA buffer supplemented with 
complete protease inhibitor cocktail (Sigma) using 1,5 mL Eppendorf tubes. Pellets were 
resuspended and kept in ice for 15 minutes before centrifugation for 15 minutes at 4°C and 13000 
rpm. After centrifugation the supernatant was transferred in new eppendorf tubes and protein 
quantification was performed using Bradford standard curve method.  
 
10.2   Bradford standard curve method and protein measurement 
The standard curve is a quantitative research tool, a method of plotting assay data that is used to 
determine the concentration particularly of proteins. The assay is first performed with various 
known concentrations of a substance similar to that being measured. A standard curve for protein 
concentration is often created using known concentrations of bovine serum albumin (BSA). The 
Bradford assay is a colorimetric assay: the reagent Coomassie Brilliant Blue turns blue when it 
binds to arginine and aromatic amino acids present in protein. The intensity of the color is measured 
at 595 nm, which is the maximum absorbance (Amax) frequency of the blue dye, using a 
spectrophotomete, and the greater the absorbance, the higher the protein concentration. The data 
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obtained are used to make the standard curve, plotting concentration on the X axis, and assay 
measurement on the Y axis. The same assay is then performed with samples of unknown 
concentration. To analyze the data, one locates the measurement on the Y-axis that corresponds to 
the assay measurement of the unknown substance and follows a line to intersect the standard curve. 
The corresponding value on the X-axis is the concentration of substance in the unknown sample. 
 
Standard curve was done by pipetting 0,  0.5,  1, and 2 mg/mL BSA in 75 μL of Comassie Brillant 
Blue a 96-well plate (two repetitions for each concentration). Wells were shaken gently and 
absorbance at 595 nm (A595) measured in each well with a microplate reader (Revelation v4.21, 
Dynex Technologies) and the background from wells containing only the colorant subtracted. A 
dose-dependent curve was made as described previously, using Excel program. The quantification 
of proteins (in lysis buffer) in each supernatant collected after centrifugation was done following the 
same protocol described before: 5 μL of supernatant was transferred in 75 μL of Comassie Brillant 
Blue in a well of a 96-well plate (two repeats for each sample) and then the absorbance at 595 nm 
was measured. The measures of absorbance obtained for all the sample were reported in Excel 
program and the software calculates the protein concentration for each sample on the base of the 
BSA standard curve done before. The same program was used to calculate the μL of sample 
containing 5, 10 and 20 μg of proteins: these  were the concentration loaded in 12%-SDS 
electrophoresis trying to find the correct quantity of protein to load and optimize the results. 
 
10.3     SDS- PAGE  Electrophoresis physical bases 
In this technique proteins are exposed to ionic detergent SDS (sodium dodecylsulfate) before and 
during gel electrophoresis.  The solution of proteins to be analyzed is first mixed with SDS, an 
anionic detergent which denatures secondary and non–disulfide–linked tertiary structures, and 
applies a negative charge to each protein in proportion to its mass .  SDS denatures proteins, 
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causing multimeric proteins to dissociate into their subunits, and all polypeptide chains are forced 
into extended conformations with similar charge.  SDS treatment eliminates the effects of 
differences in shape so that chain length, which reflects mass, is the sole determinant of the 
migration rate of proteins in SDS- polyacrylamide electrophoresis. 
 
When a mixture of proteins is loaded into a gel and an electric current applied, smaller proteins 
migrate faster than larger proteins through the gel.  The rate of movement is influenced by the gel’s 
pore size and the strength of the electric field.  The pores in a highly cross-linked polyacrylamide 
gel are quite small and this gel could resolve small proteins and peptides. Two sequential gels are 
used: the top gel, called the stacking gel, is slightly acidic (pH 6.8) and has a low (5%) acrylamide 
concentration to make a porous gel and the lower gel, called the separating, or resolving gel, is more 
basic (pH 8.8), and has a higher polyacrylamide content (in our case 12%), which causes the gel to 
have narrower channels or pores. Both gels contain only Cl- as the mobile anion. The tank buffer 
has glycine as its anion, at a pH of 8.8. When electrophoresis begins, glycine enters the stacking gel, 
where equilibrium favors the zwitterionic form with zero net charge. The glycine front moves 
slowly through the stacking gel, lagging behind the strongly charged, smaller Cl- ions. As these two 
current carrying species separate, a region of low conductivity, with a consequent high voltage 
drop, is created between them. This zone (Kohlarsch discontinuity) "sweeps" the proteins rapidly 
through the large pores of the stacking gel, collecting the sample and depositing it at the top of the 
resolving gel in a focused narrow band. When the Kohlrasch discontinuity enters the resolving gel, 
the increase in pH ionizes the glycine so that it runs faster, dissipating the discontinuity. This allows 
the proteins to unstack and separate through the small pore resolving gel. 
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10.4   SDS- PAGE  electrophoresis protocol 
12% Resolving Gel for Tris-glycine SDS-Polyacrylamide Gel Electrophoresis was made mixing 4.9 
mL H20, 6 mL 30% acrylamide mix, 3.8 mL 1.5M Tris (pH 8.8), 150 μL 10% SDS, 150 μL 10% 
ammonium persulfate and 6 μL TEMED. The resolving gel was left to set between two assembled 
glass plates.  
5% Stacking Gel  for Tris-glycine SDS-Polyacrylamide Gel Electrophoresis was made mixing 4.1 
mL H20, 1 mL 30% acrylamide mix, 750 μL 1.0M Tris (pH 6.8), 60 μL 10% SDS, 60 μL 10% 
ammonium persulfate and 6 μL TEMED. The stacking gel was put up the resolving gel,  
between the same two assembled plates and a 20-well comb (1.5mm thick) was inserted 
immediately before gel polimerization. After that, gel was allowed to set. The two glass plates 
containing both gels in polimeryzed form were then placed into a tank full of 10x Running Buffer 
(0.25 M Trizma base, 1.92 M glycine, pH 8.3), the comb gently removed, and the 5μ of protein per 
sample were loaded into the wells. In the first well 5 μL of Ladder was loaded.  Before loading, the 
samples were mixed to 2x Sample Buffer in 1:2 ratio ( Sample Buffer: 130 mM Tris-Cl pH 8, 20% 
v/v Glycerol, 4.6% w/v SDS, 0.02% Bromophenol blue, 2% DTT) and boiled 5 minutes at 90° C 
for a complete denaturation. After loading, proteins were run by the application of a constant 
current of 130 mV. 
 
10.5    Protein transfer 
This  analytical technique  involves the immobilization of proteins on membranes and detection of 
specific proteins in a given sample using monoclonal or polyclonal antibodies. In order to make the 
proteins accessible to antibody detection, they were moved from within the gel onto a 
polyvinylidene difluoride (PVDF) membrane. The membrane was placed on top of the gel, and a 
four filter papers placed on top of each side. All the components of the assembled “sandwich” were 
pre-wet in 1x Transfer Buffer and then the entire stack was placed in the  semi-dry blotting transfer 
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system. It was necessary to put the membrane between the gel and the cathode, allowing the current 
and proteins to move in that direction. A current of 22mV was  applied for 1,15 hours to pull 
proteins from the gel into the PVDF membrane maintaining the organization they had within the 
gel.  
 
 10.6     Blocking 
The PVDF membrane was placed in a 50 ml tube containing 10 ml 2% milk (in TBST: Tris 
Buffered Saline-Tween ) solution and kept in the blocking solution for 1 hour at room temperature 
with shaking. This phase is important to avoid or reduce at least the background given by an 
aspecificity of the antibodies used in the following steps. 
 
10.7   Ibrydization with primary and secondary antibodies 
The membrane was incubated with primary Antibody/es diluted in 10 ml 2% milk solution 
overnight at 4°C. The day after, primary Ab in excess were removed by 5 10 minutes TBST  
washes, followed by incubation for 1 hour Rabbit-HRCP conjugated secondary antibody diluted in 
10 ml 2% milk solution. Also the excess of this Ab was removed by 5 10 minutes TBST washes. 
The table below shows the antibodies used to detect the presence and the amount of β3-Tubulin and 
CitH3  in chick cells treated with Thapsigargin and Cl-amidine. CitH3 was studied also in LAN5 
cells using the same approach.  
 
Protein of interest 1ry antibody origin 1ry dilution 2ry antibody 2ry dilution 
B3-Tubulin Tuj1 mouse 1/10 000 anti- mouse HRCP 1/ 5000 
Citrullinated Histone 3 (CitH3) CitH3 rabbit 1/ 1000 anti-rabbit HRCP 1/ 4000 
Actin Actin rabbit 1/ 5000 anti-rabbit HRCP 1/4000 
 
 
Table 6: primary and secondary antibodies used for western blotting. 1ry: primary; 2ry: secondary 
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10.8   Development and detection by Enhanced chemiluminescence 
Enhanced chemiluminescence is a common technique for a variety of detection assays in biology. A 
horseradish peroxidase enzyme (HRP) is tethered to the molecule of interest through labeling an 
immunoglobulin that specifically recognizes the molecule, in this case the secondary antibody. This 
enzyme complex, then catalyzes the conversion of the enhanced chemiluminescent substrate 
luminol, into a sensitized reagent in the vicinity of the molecule of interest, which on further 
oxidation by hydrogen peroxide, produces a triplet (excited) carbonyl which emits light when it 
decays to the singlet carbonyl. The reaction with luminol in the presence of modified phenols, 
greatly enhance light emission. 
 
Equal volumes of  Enhanced Luminol Reagent and Oxidizing Reagent were mixed in one eppendorf 
tube to prepare the Western Lightening Chemiluminescece Reagent and this solution was pour on 
the membrane and incubated 1 minute, at room temperature. Excess of chemiluminescence reagent 
was removed by drying with paper for 5-10 sec. The membrane was then placed between two 
plastics sheet protectors avoiding any air bubbles and the blot brought to the developing room 
where in the dark, a photographic film was placed on top of the membrane. The film was exposed in 
a closed box varying the time as needed for optimal detection and then developed and analyzed. 
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RESULTS 
 
1     Chick embryo development  and PAD3 Expression Pattern 
 
Embryos in different developmental stages have been dissected to isolate specific tissues and cells 
from which I extracted mRNA and proteins. Some of chick embryonic stages are indicated in 
Fig.11. The first mRNA analysis was carried out on Pad3 transcript in homogenized of chick spinal 
cord  dissected by embryos in day (or stage) 5, 11 and 15 by RT-PCR (Fig.12). Then, Pad3 mRNA 
has been studied in homogenized of different neural tissues and skin dissected from embryos in 
days and 3, 5, 7, 11, 15, as indicated in Fig.13. This first RNA analysis were used to investigate on  
a possible relationship between PAD3 expression and neural differentiation. Fig.12 and Fig.13 
show that PAD3 expression seems to increase with development in all the tissues chosen for this 
study, especially after E5 and going through the latter stages.  This first result suggests that PAD3 
may have a role during development or related to that. 
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Fig. 11: Stages of chick embryo development. Modified from website /www.summagallicana.it/lessico/e/embrione  di pollo.htm 
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2     Pad3 and β3-Tubulin expression in chick E7 cells 
 
In double-immunostainings indicate in Fig.14-17 β3-Tubulin has been chosen as neural marker to 
study if PAD3 activity may be related specifically with neuronal development of chick immature 
 
 cPAD3 198bp  
LANES:  1           2         3          4         5         6        7          8         9        10      11        12        13        14       15 
 
 
 
Fig. 12: Pad3 transcripts in spinal cord cells collected from embryonic days 5, 11 and 15. PAD3 expression seems to 
increase with aging from day 5 to day 10. GAPDH has been used as positive control. The highest band at day11 come 
from DNA contamination. 
 
 
Fig. 13: RT-PCR for Pad3 and GAPDH (housekeeping control) mRNA in different homogenized tissues during chick 
development. Lane : Ladder Lane 2: E3 embryo Lane 3: E5 brain; Lane 4: E5 spinal cord (SC); Lane 5: E5 other parts; 
Lane 6:E7 embryo; Lane 7: E11 forebrain (FB); Lane 8:E11 midbrain (MB;) Lane 9:E11 Hindbrain (HB); Lane 10: E11 
SC; Lane 11: E11 Skin;  Lane 12: E15 Forebrain (FB);  Lane 13: E15 MB;  Lane 14: E15 HB;  Lane 15: E15 SC; 
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   100 bp- 
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   100 bp- 
 
 
 
cGAPDH 158bp 
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neural cells.  β3-Tubulin and PAD3 proteins were studied contemporarily in chick midbrain cells 
(passage 27) from embryo at day 7. PAD3 expression, distribution and its relationship with β3-
Tubulin expression were studied either on cells  grown in proliferating medium which kept them 
undifferentiated (Fig.14 and Fig.15) or in cells grown for 48 hours in differentiating medium which 
pushed them through neuronal differentiation (Fig.16 and Fig.17). 
Several immunostainings have identified PAD3 as an enzyme constitutively expressed in chick 
cells, both in  in cell positive and negative for the neuronal marker ß3-tubulin. As no differences in 
the intensity of 596 anti-rabbit antibody (red) have been found between ß3-tubulin-positive and 
negative cells (green),  PAD activity does not seem to be related to ß3-tubulin-positive expression. 
 
       2.1   Proliferating medium                                                                                      
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                          
 
 
 
Fig.14: Detection of PAD3 (red) and β3-Tubulin (green) by immunostainings in chick MB cells at passage 27 grown in 
proliferating medium. This staining has been performed after two days from plating.   
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          Fig.15: Detection of PAD3 (red) and β3-Tubulin (green) by immunostainings in chick MB cells at passage 27 
grown in proliferating medium. Higher magnification 
 
 
2.2    NeurobasalA medium                                                                                               Figure 16 
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Figure 16-17: Detection of PAD3 (red) and β3-Tubulin (green) by immunostainings in chick MB cells at passage 27 
grown in differentiating medium.  
 
 
 
 3     Methylene Blue assay dose-dependent curves and statistic 
      
Dose dependent curves were designed by calculating the means of absorbance values at 650 nm 
(A650)  for each dose of thapsigargine and Cl-amidine tested. T-test and AVOVA-1 were used then 
as statistical analysis (carried out by using Excel program) to find and choose the maximum non 
toxic concentration of these chemicals. 
By T-test (two tail) the mean of cell survival (A650) in each concentration of thapsigargine and Cl-
amidine has been compared with the mean of cell survival (groups) in the control, dose 0, to study if 
there are statistical differences. High standard error is due to the small number of repetitions for 
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each dose from which means has been calculated. ANOVA-1 was then used to compare means 
between all the groups and to decide if at least two groups (cell survival due to a specific dose of the 
chemical) are statistically different from each other (null hypothesis rejected) or not (null 
hypothesis confirmed). Both T-test and ANOVA-1 has been necessary to the choice of the highest 
non-toxic concentration of thapsigargine and Cl-amidine to use in my experiments. 
In the case of thapsigargine, T-test shows statistical differences between the means of each 
concentration and the control, dose0 , as indicates in Table7. This result suggests that all the doses 
of thapsigargine tested cause a rate of cell death. On the other side ANOVA-1 (Table8) indicates no 
statistical differences between means of the all groups analyzed in the same time suggesting that 
each concentration of thapsigargine tested on chick MBcells has the same rate of toxicity. On this 
base, 10µM thapsigargine has been chosen as dose to use in all the experiments requiring 
thapsigargine. T-test and ANOVA-1 for Cl-amidine doses in proliferating medium find statistical 
differences between the means of each concentration and the control, dose0 , (as indicates in 
Table9) but no differences between means of the all groups (Table10) as in the case of 
thapsigargine. 200µM has been chosen as the highest non-toxic concentration of Cl-amidine to use 
in proliferating medium. When the doses of Cl-amidine were assessed in differentiating medium a 
different result has found: while t-Test in Fig.11 still shows statistical differences between each 
concentration and the control, ANOVA-1 (Fig.12) rejects the null hypothesis finding statistical 
differences between all the means. However, as this difference seems to be due mainly to the high 
standard error, it has been decided to use 200µM Cl-amidine also in differentiating medium. At the 
beginning of this assay I decided to test 10μM thapsigargine and 200μM Cl-amidine as highest 
concentrations according to what found in several publications, and methylene blue assay 
confirmed they are not toxic for cells. The relationship among cell survival (A650 on Y-axis ) and 
doses of the chemical (X-axis), for each of the three assays, is qualitatively shown by dose-
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dependent curves (Fig.18, Fig.19 and Fig.20). Such curves have a non linear trend which 
demonstrate that the statistical analysis done are influenced by an high standard error. 
 
3.1 Thapsigargine in Proliferating medium 
3.1.1 t-Test 
 
Table 7 
t-Test Variable 1 Variable 2  t-Test Variable 1 Variable 2  t-Test Variable 1 Variable 2 
 doses 0 0,25   doses 0 0,5   doses 0 1 
                    
Mean 0,221 0,1793333  Mean 0,221 0,2073333  Mean 0,221 0,1683333 
Variance 0,000019 0,0006523  Variance 0,000019 0,0030573  Variance 0,000019 0,0032723 
Observations 3 3  Observations 3 3  Observations 3 3 
Pearson Corr -0,9386522    Pearson Corr 0,2779884    Pearson Corr -0,8442023   
H0 0    H0 0    H0 0   
df 2    df 2    df 2   
t Stat 2,4323486    t Stat 0,4363925    t Stat 1,4971764   
P(T<=t) one-tail 0,0677508    P(T<=t) one-tail 0,3525714    P(T<=t) one-tail 0,1365193   
t Critical one-tail 2,9199856    t Critical one-tail 2,9199856    t Critical one-tail 2,9199856   
P(T<=t) two-tail 0,1355017    P(T<=t) two-tail 0,7051428    P(T<=t) two-tail 0,2730386   
t Critical two-tail 4,3026527    t Critical two-tail 4,3026527    t Critical two-tail 4,3026527   
 
t-Test Variable 1 Variable 2  t-Test Variable 1 Variable 2 
 doses 0 2,5   doses 0 10 
             
Mean 0,221 0,1453333  Mean 0,221 0,133 
Variance 0,000019 0,0076163  Variance 0,000019 0,002361 
Observations 3 3  Observations 3 3 
Pearson Corr -0,6322157    Pearson Corr 0,3399443   
H0 0    H0 0   
df 2    df 2   
t Stat 1,4547397    t Stat 3,2233495   
P(T<=t) one-tail 0,1414882    P(T<=t) one-tail 0,0421301   
t Critical one-tail 2,9199856    t Critical one-tail 2,9199856   
P(T<=t) two-tail 0,2829763    P(T<=t) two-tail 0,0842603   
t Critical two-tail 4,3026527    t Critical two-tail 4,3026527   
        
Table7: The t-test compare the means of two groups (cell survival in a specific doses of thapsigargine) and assesses 
whether they  are statistically different from each other. Statistical significance chosen: 0,05. Dose0- dose0,25= p-
value 0,135>0,05; dose0-dose 0,5=p-value 0,705>0,05; dose0-dose 1,0=p-value 0,273>0,05; dose0-dose 2,5=p-value 
0,283>0,05; dose0-dose 10=p-value 0,084>0,05. High standard error due to a small number of repetitions for each 
dose 
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3.1.2  ANOVA-1 
 
  Table 8 
ANOVA: Single Factor         
          
Groups Count Sum Average Variance 
Dose 0 3 0,663 0,221 0,000019 
Dose 0,25 3 0,538 0,179333 0,000652 
Dose 0,5 3 0,622 0,207333 0,003057 
Dose 1,0 3 0,505 0,168333 0,003272 
Dose 2,5 3 0,436 0,145333 0,007616 
Dose 10 3 0,399 0,133 0,002361 
 
Source of Variation SS df MS F P-value F crit 
Between Groups 0,017597 5 0,003519 1,243722 0,348404 3,105875 
Within Groups 0,033957 12 0,00283       
Total 0,051554 17         
 
Table 8 ANOVA-1: analysis of  variance compares means of all the groups (cell survival in a specific dose of     
thapsigargine) contemporary. Statistical significance chosen : 0,05 As F= 1,24<F crit= 3,106 and p-value 0,348>p crit 
0,05 the null hypothesis is confirmed: there are no statistical differences between the means of the groups analyzed.  
 
 
 
    3.1.3   Dose-Dependent Curve 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure18: Dose dependent curve for thapsigargine doses in chick cells grown in proliferating medium. X-axsis 
concentrations of thapsigargine (µM);  Y-axis= (A650). 
 
 
A (650 nm) 
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 3.2     Cl-amidine in Proliferating medium 
     
3.2.1  t-Test 
                                                                                                                         Table 9 
 
t-Test Variable 1 Variable 2  t-Test Variable 1 Variable 2 
Doses 0 25  Doses 0 50 
             
Mean 0,1113333 0,087  Mean 0,1113333 0,1026667 
Variance 0,000439 0,0007843  Variance 0,000439 0,0007463 
Observations 3 3  Observations 3 3 
Pearson Corr 0,6527039    Pearson Corr -0,4673316   
H0 0    H0 0   
df 2    df 2   
t Stat 1,9708148    t Stat 0,3619149   
P(T<=t) one-tail 0,0937668    P(T<=t) one-tail 0,3760386   
t Critical one-tail 2,9199856    t Critical one-tail 2,9199856   
P(T<=t) two-tail 0,1875336    P(T<=t) two-tail 0,7520772   
t Critical two-tail 4,3026527   
 
 t Critical two-tail 4,3026527   
 
 
 
t-Test Variable 1 Variable 2  t-Test Variable 1 Variable 2 
Doses 0 100  Doses 0 200 
             
Mean 0,1113333 0,0906667  Mean 0,1113333 0,0996667 
Variance 0,000439 0,0006323  Variance 0,000439 0,0004603 
Observations 3 3  Observations 3 3 
Pearson Corr 0,0483988    Pearson Corr -0,9754413   
H0 0    H0 0   
df 2    df 2   
t Stat 1,1206243    t Stat 0,4794521   
P(T<=t) one-tail 0,1894717    P(T<=t) one-tail 0,3394631   
t Critical one-tail 2,9199856    t Critical one-tail 2,9199856   
P(T<=t) two-tail 0,3789433    P(T<=t) two-tail 0,6789261   
t Critical two-tail 4,3026527    t Critical two-tail 4,3026527   
 
Table9: The t-test compare the means of two groups (cell survival in a specific doses of Cl-amidine) and assesses 
whether they  are statistically different from each other. Statistical significance chosen: 0,05. Dose0- dose25= p-value 
0,187>0,05; dose0-dose50=p-value 0,752>0,05; dose0-dose100=p-value 0,379>0,05; dose0-dose200=p-value 
0,679>0,05;. High standard error due to a small number of repetitions for each dose. 
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3.2.2  ANOVA 1 
   
ANOVA: Single Facto         
          
Groups Count Sum Average Variance 
Dose 0 3 0,334 0,111333 0,000439 
Dose 25 3 0,261 0,087 0,000784 
Dose 50 3 0,308 0,102667 0,000746 
Dose 100 3 0,272 0,090667 0,000632 
Dose 200 3 0,299 0,099667 0,00046 
 
 
Source of Variation SS df MS F P-value F crit 
Between Groups 0,00113 4 0,000283 0,461358 0,762803 3,47805 
Within Groups 0,006125 10 0,000612       
Total 0,007255 14         
 
Table 10 ANOVA-1: analysis of  variance compares means of all the groups (cell survival in a specific dose of Cl-
amidine) contemporary. Statistical significance chosen : 0,05 As F= 0,461<F crit= 3,478 and p-value 0,763 >p crit 
0,05 the null hypothesis is confirmed: there are no statistical differences between the means of the groups analyzed.  
 
 
 
 
3.2.3  Dose-Dependent Curve 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Dose dependent curve for Cl-amidine doses in chick cells grown in proliferating medium. X-axsis 
concentrations of Cl-amidine (µM);  Y-axis= (A650). 
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 3.3     Cl-amidine in Differentiating medium 
 
 
 
3.3.1  t-Test 
                                                                                                                                                          Table 11 
 
t-Test Variable 1 Variable 2  t-Test Variable 1 Variable 2 
  0 25    0 50 
             
Mean 0,046 0,0528571  Mean 0,046 0,0591429 
Variance 0,0002798 0,0003299  Variance 0,0002798 0,0008833 
Observations 7 7  Observations 7 7 
Pearson Corr 0,5676017    Pearson Corr -0,3788206   
H0 0    H0 0   
df 6    df 6   
t Stat -1,114873    t Stat -0,8861461   
P(T<=t) one-tail 0,1537792    P(T<=t) one-tail 0,2048234   
t Critical one-tail 1,9431803    t Critical one-tail 1,9431803   
P(T<=t) two-tail 0,3075583    P(T<=t) two-tail 0,4096468   
t Critical two-tail 2,4469118    t Critical two-tail 2,4469118   
 
 
t-Test Variable 1 Variable 2  t-Test Variable 1 Variable 2 
  0 100    0 200 
             
Mean 0,046 0,0274286  Mean 0,046 0,0282857 
Variance 0,0002798 0,0003392  Variance 0,0002798 6,581E-05 
Observations 7 7  Observations 7 7 
Pearson Corr 0,1099695    Pearson Corr -0,6667433   
H0 0    H0 0   
df 6    df 6   
t Stat 2,0926951    t Stat 2,0424151   
P(T<=t) one-tail 0,0406474    P(T<=t) one-tail 0,0435762   
t Critical one-tail 1,9431803    t Critical one-tail 1,9431803   
P(T<=t) two-tail 0,0812947    P(T<=t) two-tail 0,0871525   
t Critical two-tail 2,4469118    t Critical two-tail 2,4469118   
 
Table11: The t-test compare the means of two groups (cell survival in a specific doses of Cl-amidine) and assesses 
whether they  are statistically different from each other. Statistical significance chosen: 0,05. Dose0- dose25= p-value 
0,307>0,05; dose0-dose50=p-value 0,410>0,05; dose0-dose100=p-value0,0813>0,05; dose0-dose200=p-value 
0,087>0,05. High standard error due to a small number of repetitions for each dose. 
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3.3.2 ANOVA 1 
 
ANOVA: Single Facto         
          
Groups Count Sum Average Variance 
Dose 0 7 0,322 0,046 0,00028 
Dose 25 7 0,37 0,052857 0,00033 
Dose 50 7 0,414 0,059143 0,000883 
Dose 100 7 0,192 0,027429 0,000339 
Dose 200 7 0,198 0,028286 6,58E-05 
 
Source of Variation SS df MS F P-value F crit 
Between Groups 0,005778 4 0,001444 3,805018 0,012838 2,689628 
Within Groups 0,011389 30 0,00038       
Total 0,017166 34         
 
Table 10 ANOVA-1: analysis of  variance compares means of all the groups (cell survival in a specific dose of Cl-
amidine) contemporary. Statistical significance chosen : 0,05 As F= 3,80>F crit= 2,69and p-value 0,01 <p crit 0,05 
the null hypothesis is rejected: at least two means are statistically  different from each other. 
 
 
 
     3.3.3  Dose-Dependent Curve                                                                                  Figure 20 
 
 
 
 
 
 
 
 
 
 
Figure 19: Dose dependent curve for Cl-amidine doses in chick cells grown in differentiating medium. X-axsis 
concentrations of Cl-amidine (µM);  Y- axis= (A650). 
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4      Effect of pifithrin on proliferation of chick MBcells 
 
Pifithrin is a chemical which inhibit p53 and it has been used to study if the activity of PAD in 
chick cells depends to p53-PAD interaction, as what has been shown for PAD4 in mice. (Li et al., 
2010). Pifithrin speeds up cell growth by inhibition of p53 promoting tumors; for this reason 
different doses of the chemical were assessed on chick cells, looking for the highest not-toxic and 
not-tumorigenic concentration. After culturing chick midbrain cells (E7) in 24 well plate, cells were 
treated with 10, 15, 20, 50 and 100μM of pifithrin (20 mg/mL in DMSO), other cells were treated 
with 0,2% DMSO. Samples were incubated at 37°C and checked by time-lapse microscopy after 2, 
4, 6 and 12 hours from the treatment. Fig.21 shows cells after 6 hours from the treatment; after 2 
and 4 hours no differences between doses were found (results not shown). Cell growth speed was 
compared after 6 hours incubation the increasing doses of pifithrin. DMSO resulted to be 
tumorigenic as already known (Busbry et al., 1984) as cells treated with 0,2% DMSO (1μL in 500 
μL differentiating medium) had an higher growth speed then the untreated controls. Untreated cells 
and cells incubated with 15 and 20μM pfithrin showed the same growth rate while 50μM pfithrin 
speed-up cell growth, resulting an high dose with tumorigenic effect. 100μM concentration had 
indeed a toxic effect on chick cells which died rapidly. By using 32X objective I observed cell 
morphology and eventually differences between the samples. As indicates in Fig.22 no 
morphological differences were found between control, DMSO and the three assessed 
concentrations of pifithrin. According to these results I chose 20 μM as highest not-toxic and not-
tumorigenic concentration of pifithrin to use as treatment for chick MBcells grown in proliferating 
medium. The chosen dose of pifithrin was tested then on chick MBcells grown in differentiating 
medium (Fig.23). As neither cell growth rate nor cell morphology seem to be affected by 20µM of 
pifithrin this concentration has been the chosen for both media. All the experiments here described 
has been repeted in triplicate for three times.  
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4.1 Proliferating medium                                                                                                 Fig21 
 
 
 
 
 
 
 
  
 
 
Fig22 
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig21: Cell growth of chick MB cells tested in proliferating15, 20, 50 and 100μM pifithrin-containing medium  after 6 
hours from the treatment. Untreated cells and cells incubated with 15 and 20μM pfithrin show the same growth rate 
while 50μM pifithrin  seem to speed up cell growth rate. 100μM concentration has indeed a toxic effect. Cells were 
monitored for 12 hours by using Time-lapse microscope.  Figure 22: cell morphology after pifithrin treatment (32X 
objective). It  seems to be not affected by treatment e no dose-effect seems to be involved.  
 
                      Control                                        DMSO                                       15μM Pifithrin 
             20 μM pfithrin                           50 μM pfithrin                         100 μM pfithrin    20 t rin             50 μM pf thrin          100 μM pfithrin 
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4.2 Differentiating medium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Cell growth and morphology of chick MB cells tested in  proliferating 20μM pifithrin-containing medium 
after 6 hours from the treatment. Cell morphology does not seem to be affected by pifithrin treatment at any of the 
concentrations tested. Cells were monitored for 12 hours by using Time-lapse microscope. 
  
 
5     Cl-amidine prevents cell-death in thapsigargine treated cells  
 
5.1   Cell death and survival 
Cells treated for 20 hours with 20µM pifithrin, 10 µM thapsigargine, 200 µM Cl-amidine and with 
200 µM Cl-amidine + 10 µM thapsigargine, were collected and then western blot was performed to 
study if these drugs could change ß3-tubulin  levels in chick cells suggesting a role of PAD3 also 
during neuronal differentiation. Western blotting  for  ß3-tubulin could not be carry on in chick cells 
grown in differentiating medium because the overnight thapsigargine treatment in differentiating 
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medium induced significant cell death, but such cell death was reduced by pretreating the cells with 
Cl-amidine (Figure 24). These cells, were PAD are inhibited, survive and this suggest an activity of 
PAD3  during cell death (results not shown). When I tried to keep each treatment for longer, after 
30 hours Cl-amidine was insufficient to antagonize PAD3 activity (where activated by 
thapsigargine). Maybe an higher dose of Cl-amidine is necessary for longer periods. In cells grown 
in proliferating medium thapsigargine and Cl-amidine did not affect cell survival and no differences 
with the untreated controls have been found. 
 
5.2    Tuj1 expression in control and treated cells 
 
To what concern β3-Tubulin amount, it seems to be the same as in chick cells used as negative 
control as in cells treated with thapsigargine or Cl-amidine or with both drugs, as shown in Fig.24. 
These chemicals did not affect  β3-Tubulin synthesis in chick cells in both proliferating  and 
differentiating medium but that is impossible to say anything about thapsigargine  effect during 
neuronal differentiation (differentiating medium) because cells cannot survive. In Cl-amidine 
pretreated cells, kept growing in differentiating medium,  β3-Tubulin amount appears to be less than 
in the other samples but that could be correlated with a block of differentiation process to allow cell 
activity and protein synthesis directed to survival. Cl-amidine was in fact insufficient to prevent 
PAD-dependent cell-death (activation with thapsigargine) after periods longer than 20 hours.  
Furthermore in the same experiment chick cells treated with the p53 inhibitor, pifithrin, did not 
show any differences in ß3-tubulin amount and cell survival, p53 does not seem to be required for 
PAD activity, but no other experiments have been carried on in this way and we cannot be sure of 
this first result and conclude anything about.  
In conclusion, given that PAD3 expression was observed both in cell positive and negative for the 
neuronal marker ß3-tubulin (immunostainings showed in Fig14, Fig.15, Fig.16 and Fig.17)  , and 
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that Cl-amidine did not affect expression  ß3-tubulin, as indicated by western blotting, a role for 
PAD in neuronal differentiation does not seem to be likely. 
 
 
                    
             
Fig24: Western blotting detecting ß3-Tubulin and actin (loading control) in chick MB cells grown in proliferating and 
differentiating medium with different compounds for 20 hours. Treatments from left to right: untreated control, 20 µM 
pifithrin, 10µM thapsigargine, 200 µM Cl-amidine, 200 µM Cl-amidine + 10 µM thapsigargine (thapsigargine was 
added 15 minutes after Cl-amidine). Neither Cl-amidine nor the other treatments affect expression of ß3-tubulin. 
Intrestengly Cl-amidine prevent PAD-dependent cell-death due to PAD activation by thapsigargine. 
  
 
Although neuronal differentiation does not seem to be depended from PAD activation,  what is 
indicated in Fi.12 and Fig.13 confirms that Pad3 transcript increase with time of chick development 
and suggest a relationship between PAD3 expression and the loss spinal cord ability  to regenerate 
following injury in advanced developmental stages. That raises the issue that PAD3 has a role 
during apoptosis confirming that observed during the experiments of spinal cord injury where, 
consistent with differences in up-regulation of PAD3 in spinal cord injured at E11 and E15, more 
extensive citrullination as well as apoptosis and significant tissues loss were observed by 24 hours 
in injured E15 spinal cords and where treatment with specific PAD inhibitor, Cl-amidine, reduced 
apoptosis and cavitation of the chick spinal cord. 
The fact that apoptosis, cavitation, citrullination and tissues loss are more significant at latter stage 
E17 rather than at the earlier one E11 (Lange et al; 2010 submitted) may be due to an increasing 
expression of PAD3 during chick development, from immature progenitors to mature and 
differentiated cells. In this way, cells in the letter stages of development have an higher amount of 
this enzyme involved in apoptosis and that is why it is find a stronger response to injury. This 
results are important because confirm what observed in spinal cord injury experiments showing that 
       80 kDa- 
      50 kDa- 
           25 kDa-                            
        
       40 kDa- 
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β3-Tubulin 
Actin 
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chick MB cell is a good model to study injury response in vitro, and  enhancing the idea that PAD3 
could have a role during senescence and apoptosis mechanisms and excluding PAD3 activity in 
promoting neuronal differentiation.  
As  PAD3 resulted constitutively expressed in chick cells, without any difference in the amount and 
localization between ß3-tubulin-positive and negative cells, as indicated by immunocytochemistry, I 
did not repeat the same experiment using neural markers specific to glial cells and atrocytes and I 
assumed that the increase of PAD3 activity during development should not be related to the 
differentiation in a specific neural cell line. 
 
 
6    PAD3 and CitH3 in immunocytochemistry 
 
The results obtained till now may underline a role of PAD3 associated with senescence and cell 
death. Following this new hypothesis then I studied the effects of PAD inhibition, using Cl-amidine, 
and PAD activation, using thapsigargine to raise intracellular calcium, on expression and cellular 
localization of PAD3 and on citrullination of a PAD nuclear-target, histone 3 (H3) in cMB cells. 
Chick cells from E7 stage and passage 12 (P12) grown in 24-well plate were treated using Cl-
amidine, thapsigargine and both treatments as described before. After two hours an immunostaining 
was performed to see if the different treatments give changes in PAD3 and CitH3 amount (intensity 
of signal) and localization in the same cell line. I used the following antibodies: rabbit anti-PAD3 
(Chemicon, 1:200) , rabbit anti-CitH3 ( Chemicon, 1:250), Alexa 488-conjugated goat anti-rabbit ( 
Molecular probes 1:400). This immunostaining was repeated several times and the same experiment 
was performed in chick cells from E7 in passage 30 (P30). 
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6.1 PAD3 and CitH3 in chick in P12                                                                      Fig 25-26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25-26: (25) PAD3 immunostaining in chick MBcells at P12, after 2 hours from treatment. (26) CitH3 
immunostaining in chick MBcells at P12, after two hours from the treatment. Treatments from left to right: untreated 
 
 
Hoechst 
Hoechst 
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control, 20µM pifithrin, 10µM thapsigargine, 200 µM Cl-amidine, 200 µM Cl-amidine + 10µM thapsigargine 
(thapsigargine was added 15 minutes later then Cl-amidine). For each sample has been done a nuclear staining by 
using Hoechst dye (blue). 
 
 
Significantly, in Fig.25 PAD3 mainly localized to the nucleus in cMB cells at passage 12 following 
thapsigargine treatment, whereas it remained largely cytoplasmatic in controls and cells pre-treated 
with Cl-amidine. Citrullinated H3 (CitH3) was not restricted to the nucleus in thapsigargine-treated 
cells while it is definitely nuclear in control and Cl-amidine treated cells (Fig.26). These results 
suggest that the PAD-associated apoptotic effect is likely due to PAD activity in the nucleus and 
that increased citrullination of H3 results in its export from the nucleus.  
 
6.2 PAD3 and CitH3 in chick in P30 
 
                                                                                                                                                                           Fig27                     
 
 
 
 
 
 
 
 
Hoechst 
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Fig28                                                                                                                                                            
                                                                                 
Figure 27-28: PAD3 immunostaining in chick Mbcells at P30, after 2 hours from treatment. (26) CitH3 immunostaining 
in chick MBcells at P12, after two hours from the  treatment. Treatments from left to right: untreated control, 20µM 
pifithrin, 10µM thapsigargine, 200 µM Cl-amidine, 200 µM Cl-amidine + 10µM thapsigargine (thapsigargine was 
added 15 minutes later then Cl-amidine). For each sample has been done a nuclear staining by using Hoechst dye 
(blue). 
 
 
At P30, PAD3 was largely nuclear both in control and treated cells (thapsigargine/Cl-amidine), and 
CitH3 distribution (Fig.28) resembeld that observed at P12 following thapsigargine-treatment. No 
changes in PAD3 localization were observed upon thapsigargine/Cl-amidine-treatments at P30 
(Fig.27), unlike at P12 where PAD3 localized in the nucleus only in thapsigargine-treated cells.  
These immunostainings confirm and enhance the already existing idea that activation of chick 
peptidyl arginine deiminases-3 may occur during senescence or play a role in promoting senescence 
and cell death and add a new hypothesis: PAD3 localizes in the cytoplasm in inactive form and 
following its activation or stimulation, by unknown factors, it turns to the nucleus to act on a 
nuclear target. These results parallel to PAD4 activity observed in human MS patients and in 
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Hoechst 
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transgenic mice.  PAD4 is overexpressed and activated in the
 
CNS of MS patients and animal 
model, and
 
 translocates into the nucleus stimulated by tumor necrosis factor (TNF). PAD4 nuclear-
activity relates to increased levels of citrullinated histone3. High citrullination of histones 
consequent to PAD4
 
nuclear translocation is part of the process that leads to irreversible
 
changes in 
oligodendrocytes and may contribute to apoptosis
 
of oligodendrocytes in MS (Mastronardi et. al 
2006).  
Not only PAD3 localization but also CitH3 distribution seems to change according to PAD 
activation which seems to have a relationship with the loss of nuclear localization of CitH3 (Fig.26-
28). Western blot analysis has been done then, to study if also CitH3 amount in chick MBcells is 
affected by the same treatments. 
 
 
7 PAD3 transcript with time in culture 
 
The immunostainings described before underline a difference in PAD3 localization with aging (time 
in culture) and when activated by thapsigargine in passage 12. RT-PCR has been performed in 
chick MBcells from E7 to analyze if there are also differences in Pad3 transcript with aging. To this 
purpose we used cells at passages 10, 20 and 30. As shown in Fig.29 Pad3 transcript increases with 
time in culture from passage 10 to passage 20 and this result enhances the hypothesis of a role of 
PAD3 during senescence . 
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 8      Western blotting: PAD3 expression in chick cells 
 
 
Western blot was performed using 20μg of protein extracted from chick MBcells from E7, both in 
P12 and P30, to study if there were differences in CitH3 amount among the different treatments. 
There were used the following antibodies: rabbit anti-CitH3 (1:1000 Abcam, U.K) and HRP-
conjugated goat anti-rabbit (DAKO, 1:4000). The results obtained after 1 minute-exposure are 
reported in Fig.30. As western blotting shows no differences in the amount of CitH3 (molecular 
weight among 25 and 40 kDa) between the different treatments , all the results analyzed till now, 
suggest an increased nuclear activity of PAD3 (Fig.25 and Fig.27) and increased turnover of CitH3 
with aging (Fig.26 and Fig.28) that may be associated with cellular senescence and death. 
Citrullination of histones causes the nucleosomes to open up (weak connection among DNA and 
less basic proteins) and that could promote the transcription of genes involved in senescence and 
cell death and surely expose DNA to nucleases. At present nothing explains the movement of CitH3 
in the cytoplasm but I formulated three hypothesises: CitH3 would be replaced by H3 after the 
 
Figure 29: RT-PCR: Pad3 transcripts and GAPDH in chick MBcells at passage 10, 20 and 30. 30 cycles of PCR in 
total. The transcript increases with aging,  from passage 10 to passage 20 
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transcription of senescence/apoptosis-related genes according to gene-silencing mechanisms; 
citrullination exposes DNA to nucleases and that may be important during apoptosis where there is 
a balance between citrullinated histones that move to cytoplasm to be degradated and the activity of 
PAD3 in the nucleus in forming new citrullinated histones which increase the exposure of DNA to 
degradation. The third possibility comes from recent studies on histones: the work of Li et al. 
(2005), explains how the phospho-H3 detached from chromosomes and move to cytoplasm to act  
as mitotic-signal and play a crucial role in cytokinesis, and on this base cytoplasmatic CitH3 may be 
assumed as signal of senescence or cell death.  However, even if these are just hypothesises to 
explain the presence of CitH3 in cytoplasm which parallels to nuclear PAD3 activity, it is clear and 
proved that extranuclear accumulation of histones or modified histones occur in a early event of 
apoptosis (Gabler et al. 2004; Nur et al. 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Western blotting detecting CitH3 and actin (loading control) in chick MBcells at passege 12 and 30,  after  2 
hours from the treatments. Treatment from left to right: untreated control, 20µM pifithrin, 10µM thapsigargine, 200 
µM Cl-amidine, 200 µM Cl-amidine + 10µM thapsigargine (thapsigargine was added 15 minutes after Cl-amidine). No 
differences in the amount of CitH3 (molecular weight among 25 and 40 kDa) between the different treatments has been 
found. 
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9     LAN5 immunostainings: PAD3, PAD4 and CitH3  
 
In the following experiments I assessed by immunocytochemistry the expression of PAD3 and 
PAD4, and the response to thapsigargine and Cl-amidine treatment in LAN5 cells. As LAN5 cells 
belong to human Neuroblastoma cell lines and as they comes from embryonic child tumor, I used 
LAN5 cell line in my project to investigate if there is a  relationship between neural embryonic 
stem/progenitor-derived tumor and PADI expression like what found for PAD4 and CD34+ stem 
cells (Chang et Han, 2006;  Chang et Fang, 2010). The results are indicate in Fig.31 and Fig.32: 
PAD3 and PAD4 appeared to be mainly perinuclear, and their expression and localization was not 
affected by any drug combination. Immunocytochemistry showed that also CitH3 (Fig.33) 
localization was not affected in treated cells but the signal appears to be weakly stronger in control 
and thapsigargine-treated cells. These results parallel to what observed in P30 chick cells where 
PAD3 (Figure27) was largely nuclear both in control and treated cells (thapsigargine/Cl-amidine), 
and  no changes in PAD3 localization were observed upon thapsigargine/Cl-amidine-treatments at 
P30. Citrullinated H3 (CitH3) was not restricted to the nucleus as in P30 chick cells. These results 
suggest an increased nuclear activity of PAD3 and may be an increased turnover of CitH3 with 
aging (P30 chick cells) that may be associated with cellular senescence and death, a signaling 
promoting cell death which still remains in tumor cells even if they cannot go through apoptosis. 
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Fig.31 
Fig.31-Fig32: (Fig.31) PAD3 immunostaining in LAN5 cells after 2 hours from treatment.(Fig.31) PAD4 
immunostaining in LAN5 cells after 2 hours from the treatment. Treatments from left to right: untreated control, 20µM 
pifithrin, 10µM thapsigargine, 200 µM Cl-amidine, 200 µM Cl-amidine + 10µM thapsigargine (thapsigargine was 
added 15 minutes later then Cl-amidine). Nuclear staining with Hoechst dye (blue) 
 
     
 
           Control                 10 μM Thapsigargin        200 μM Cl-amidine          Cl-am + Thaps        
       LAN5 
 
       
 Hoechst                                                                                                                           40 X           
 
40 X  
           
          Control               10 μM Thapsigargin       200 μM Cl-amidine          Cl-am + Thaps        
       LAN5 
        
        Hoechst                                                                                                     40 X 
 
Fig.32 
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Figure 33: CitH3immunostaining in LAN5 cells, after 2 hours from the treatment.  Treatments from left to right: 
untreated control, 20µM pifithrin, 10µM thapsigargine, 200 µM Cl-amidine, 200 µM Cl-amidine + 10µM 
thapsigargine (thapsigargine was added 15 minutes later then Cl-amidine). For each sample has been done a nuclear 
staining by using Hoechst dye (blue). 
 
 
 10    PCR in LAN5 cells: PADI 1-4 and p21     
 
Here I illustrate the results of RT-PCR for p21 and PADI1-4 in LAN5 cells. This experiment has 
been carried out to the purpose of characterize the expression pattern of PADI in LAN5 cell.  
Unfortunately , as indicates in Fig.34, no PADI mRNA was found (PAD1-4) in LAN5 cells and 
PCR does not give good informations as PAD3 and PAD4 transcripts were not found neither in 
LAN5 cells nor in positive control (keratinocytes). PCR was then repeted using again the same 
primers for PAD3 and a new pair and has been run at 54°C for 35 cycles (29 cycles for the previous 
one) and the result is shown in Fig.35. In this case a weak band corresponding to the right product 
size, 167bp,  has been found, and although it is impossible to make any conclusion that give three 
 
          Control                10 μM Thapsigargin       200 μM Cl-amidine          Cl-am + Thaps        
       LAN5 
    
 Hoechst                                                                                                                           
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possibilities: PAD3 and 4 are expressed in LAN5 cells but I need to optimize the PCR conditions; 
PAD3 and PAD4 are really expressed but I need to use better primer sequences; PAD3 and 4 are 
not expressed in these cells and what observed in immunocytochemistry (Fig.31 and 32)  was due to 
cross-reaction and aspecificity of the antibodies I used. At present more studies are still needed to 
clear these first results, and if PAD3 and 4 are really expressed is still unknown. Anyway, it is 
known that PAD1 and PAD2 are not expressed in LAN5 cells but present in keratinocytes used as 
positive controls (Figure 34-35). 
 
 
 
 
 
 
 
 
Fig.34 
 
 
 
 
                  Figure35 
 
  
 
 
Figure 34: RT- PCR  for p21, PAD1 PAD2, PAD3 and PAD4 transcripts in LAN5 cells (L) and in keratinocytes (K) 
used as positive control for PADI1-3. No transcripts for PAD3 and PAD4 has been found neither in keratinocytes nor 
in LAN5 cells, while PAD1 and PAD2 mRNA has been found in the control (keratinocytes) but not in LAN5 cells 
suggesting the absence of PAD1 and PAD2 transcription in such neuroblastoma cells. 
Figure 35: RT-PCR for PAD3 transcript in LAN5 cells. There were used new sequences of PAD3 primers (the second 
ones in Table1), and 54°C as running temperature. A weak band corresponding to the right product size, 167bp,  has 
been found. 
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11    Western blotting:  CitH3 amount in LAN5 cells 
 
Western blotting has been performed also in LAN5 cells, to study if the inhibition and activation of 
PAD can influence the amount of CitH3. Also in this case, western blotting has been done after 2 
hours from treatment and incubation. As Fig.36 shows, no differences in the amount of CitH3 (mw 
among 25 and 40 kDa) were found between the different treatments as I observed in chick cells. 
 
 
 
 
 
 Figure 36: Western blotting: CitH3 amount and actin control in LAN5 cells after 2 hours from treatment. Treatment 
from left to right: untreated control, 20µM pifithrin, 10µM thapsigargine, 200 µM Cl-amidine, 200 µM Cl-amidine + 
10µM thapsigargine (thapsigargine was added 15 minutes later then Cl-amidine) 
 
 
12     Cl-amidine effect on cell adhesion  
 
Chick midbrain cells were plated in T-25 flasks in both proliferating and differentiating medium 
containing 200μM Cl-amidine to assess the effect of this chemical on chick cells when Cl-amidine 
is already present in solution at the time of plating. Flasks were checked on time lapse microscope 
after 24 and 48 hours from the plating, then the surnatant was removed and floating cells collected 
and plated in new flasks in fresh medium without Cl-amidine. When plated in the presence of Cl-
amidine, most cMB cells did not attach to the dish, but were able to do so upon removal of Cl-
amidine. Therefore their adhesion ability rather than survival appear to be affected. When cells were 
grown in neural differentiation medium (serum-free) to study a possible role of PAD in 
differentiation, such recovery was not observed. (Figure 37). 
                                                           Control       Pifithrin          Thaps          Cl-am         Thaps+Cl-am 
- 40kDa - 
     - 25kDa - 
 
- 50kDa- 
- 40kDa - 
Actin 
CitH3 
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In addition to an effect on cell death, PAD activity was found to play a role in cell adhesion (Figure 
37);  cell adhesion ability rather than survival appear to be affected when plated in the presence of 
Cl-amidine and this suggest cytoplasmatic target-proteins which need to be citrullinated to allow 
cell adhesion. As the same cells were able to attach to the dish upon removal of Cl-amidine, PAD 
inhibition seems to be reversible. When cells were grown in neural differentiation medium (serum-
free) such recovery was not observed and it could be due to a toxic effect of Cl-amidine in serum 
free medium or to an irreversible PAD-inhibition in these conditions of cultures. 
If it is PAD3 acting on these proteins or other PAD expressed in chick cells is still unknown but that 
is the most likely interpretation as according to more recent studies PAD3 results to be the only 
PAD transcript detectable in cMBcells. 
 
    5 X 
A.1      A.2   A.3     
A.3 
 B.1                                                   B.2                                                  B.3 
 
Figure 37: The pictures shows chick MB cells checked by time-lapse microscope after 48 hours from plating 
in proliferating and differentiating media containing 200μM Cl-amidine. In controls, cells attach to the dish 
and grow in both proliferating (A.1) and differentiating (B.1) medium (less in differentiating medium 
because only the neuronal progenitors are selected). Figures A.2 and B.2 shows cells after 48 hours from 
plating in both media containing 200μM Cl-amidine; a really small percentage of cells are attached and 
flatted to the flask in proliferating medium (A.2) while the greatest part of cells is rounded-up and floating. 
All cells results to be detutched and floating in differentiatin medium (B.2). Figures A.3 and B.3 shows cells 
which have been collected from the medias containing Cl-amidine and plated in fresh medium Cl-amidine 
free; cells grown in proliferating medium are able to attach to the dish and grow as in the control while 
cells collected from differentating Cl-amidine tretaed medium do not recover. 
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CONCLUSION 
 
All the studies on PAD expression in chick midbrain cells have been carried on in a relatively early 
developmental stage, E7, although at present the role of peptidylarginine deiminases in chick 
(Gallus gallus) nervous system is poorly understood. More is indicated in literature about the 
function of these enzyme in mouse ad human. In this project, several immunostainings have 
identified PAD3 as an enzyme constitutively expressed in chick cells, both in  in cell positive and 
negative for the neuronal marker ß3-tubulin, consequentially PAD activity does not seem to be 
related to  ß3-tubulin expression. Western blotting analysis suggest the same conclusion because 
ß3-tubulin amount did not change by inhibiting PAD in the presence of Cl-amidine or by activated 
them with thapsigargine. Although Pad3 transcript increases with time of chick development a  role 
for Pad during differentiation does not seem to be likely. 
One of the most important results of this project is the reduction of cell death upon PAD inhibition 
which parallels the in vivo finding in the injured chick spinal cord as shows chick MBcells as a 
good model to study spinal cord injury response in vitro. The findings of this work suggest an 
increased nuclear activity of PAD3 and increased turnover of CitH3 with aging that may be 
associated with cellular senescence and death. This study raises the issue that PAD3 has a role 
during apoptosis confirming that observed during the experiments of spinal cord injury previously 
described: the fact that apoptosis, cavitation, citrullination and tissues loss are more significant at 
latter stage E17 rather than at the earlier one E11 may be due to an increasing expression of PAD3 
during chick development, from immature progenitors to mature and differentiated cells. In this 
way, cells in the letter stages of development have an higher amount of this enzyme involved in 
apoptosis and that is why it is find a stronger response to injury. This work add to these knowledges 
that the PAD-associated apoptotic effect is likely due to PAD3 activity in the nucleus, it is 
maximum and not affected by any drug combination when PAD3 is activated and that the activation 
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of PAD3 correspond to a new distribution of the enzyme which from the cytoplasm turns to the 
nucleus. Another important finding is that PAD3 activity increases citrullination of H3 in the 
nucleus and results in its export outside the nucleus.  
In which way PAD3 responds to aging is still unknown and it is not known if the cytoplasmatic 
form is really an inactive enzyme or may have other function; according to the last experiment 
mentionated in this article, the second hypothesis seems to be the correct one as PAD activity was 
found to play a role also in cell adhesion. If it is PAD3 acting on these proteins or other PADs 
expressed in chick cells is still poorly understood but that seems to be the most likely interpretation 
as, according to more recent studies, Pad3 results to be the only PAD transcript detectable in 
cMBcells such as only PAD3 protein. These studies on PADI expression and function in chick 
nervous system are still ongoing. That is important to underline how the knowledges on PADI 
expression grow and change in the last years. In 2005 only one PAD transcript, identified as PAD2  
paralog, has been described chicken (Gallus gallus); such transcript has been found in cerebrum, 
kidney and testis of adult organisms (Balandraud et al., 2005). Three years later thanks to the 
development of genomic project and advanced genomic prediction, PADI isotypes predicted in 
birds (Gallus gallus) became three cPad1-3 (Ying et al., 2008). At present, recent studies and my 
project increase the knowledge on PADI expression in chicken showing Pad3 as the only PAD 
transcript in the nervous system of chick embryo, and PAD3 the only PAD-enzyme detectable by 
western blotting. 
. 
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